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Abstract  
Autism or autism spectrum disorder (ASD) is a very diverse neurological disorder that 
manifests specifically in children and infants between the ages of two to three years of age. 
An individual suffering is deemed as autistic and individuals suffering would be classed 
under the banner of ASD. It is observed that sufferers have impairment in their social and 
interactive skills. It has both genetic and environmental factors that contribute to its diversity 
and although the primary cause of autism is still unclear, scientist are investigating both 
factors. In this study we aimed to investigate the molecular genetics of autism in the South 
African (SA) population.  This was done in two parts, a genetic association study and a 
functional genomics (proteomic study). An association study of the 2 single nucleotide 
polymorphisms (SNPs) of the Cadherin 10 type II gene (CDH10) (rs4307059 and rs4327572) 
was investigated in the SA healthy and autistic population. The proteomic approach was used 
to determine the differential expression of genes of the healthy population and compared to 
the autistic population of African descent. In both parts of the project, objectives were 
achieved. The SNPs were successfully genotyped however no association was determined for 
autism in the SA population. The urine protein profiles with 1 dimensional (1D) and 2 
dimensional (2D) Sodium Dodecyl Sulfate-Poly Acrylamide Gel Electrophoresis (SDS-
PAGE) generated in this study has revealed the following proteins, Uromodulin, Vitelline 
membrane outer layer protein homologue, kinninogen-1, Alpha-1-Antitrypsin, Ig Kappa 
chain region C, and CD59 glycoprotein that require further investigation. The results 
indicated that six of the identified proteins were expressed in both groups but were found to 
be either quantitatively or statistically significant. However, a statistically significant 
difference was observed in the expression of one protein (Uromodulin)  which was observed 
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to be expressed in the healthy group but absent in the experimental group. However further 
investigation is required validation of these findings.  
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1. Autism 
1.1.Background to autism 
“Autism is the most severe of the pervasive developmental disorders (PDD) with primary 
symptoms of impaired social skills, delayed or non-existent language skills, and the presence 
of stereotypic, repetitive movements” (Association, 1994). It is characterized based on the 
deficiencies in social interactions, behavior patterns and language abilities of the individual 
(Sebat et al., 2007).  
 
Wilson (2011) described it as too much chaos internally in the brain and nervous system and 
this results in the child withdrawing him/herself to reduce stimulation and chaos from 
outside. Autism Spectrum Disorder (ASD) and Pervasive Developmental disorder (PDD) are 
such diverse disorders in nature and has different degrees in which they present themselves 
(Muhle et al., 2004). Individuals have one: erratic behavior, two: tend to be very sensitive 
and incapable of holding a conversation, and then at the other end of the spectrum the savant 
individuals. Savants are individuals with mental disabilities but are skilled as well typically 
limited to areas such as music, art, calendar calculating, mechanical skills and numerical 
ability (Treffert, 1999). 
 
In the United States of America a group of psychiatric and psychologists developed a set of 
criteria for assessing individuals with mental disorders named the diagnostic and statistical 
manual of disorders, manual four (DSM-IV). It is the most widely used diagnostic tool for 
ASD and for an individual to be considered autistic, he/she should display features described 
in this manual. Apart from these common features some individuals may also suffer from 
different types of disorders in communal behavior, such as sensory dysfunctions, sleep and 
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gastrointestinal disorders, seizures and mental retardation (Bauman, 2010). The manual has 
been through several revisions over the years with advances made by the scientific 
community. Charney et al.,(2002) criticized the DSM-IV manual because it did not 
effectively “reflect a neurobiological basis” for most mental disorders (Charney et al., 2002). 
In the DSM-IV manual autism disorder, Asperger’s, Retts Syndrome, Childhood 
Disintegrative disorder and Pervasive Developmental disorder Not otherwise specified (PDD-
NOS) are all categorized and diagnosed under pervasive Developmental Disorder. However 
in the DSM-V manual, Asperger’s and PDD-NOS have been removed. PDD-NOS are 
classified as a Social Communication Disorder whereas Asperger’s has become a subtype 
under ASD. The revised manual DSM-V includes a grading system of disorders based on the 
severity of the individual according to the assistance or support required (Grant and Nozyce, 
2013). 
 
1.2.Co-morbid disorders 
This complex disorder has been associated with various other disorders due its diverse nature 
and symptoms. It has been recorded back in time as early as 1911 by a psychiatrist, Eugen 
Bleuler although the term applied to adult schizophrenia. Schizophrenia along with other 
disorders such as Rett’s Syndrome (RS), Fragile X syndrome (FraX), Attention Deficit 
Hyperactivity Disorder (ADHD), Asperger’s, Severe Mental retardations and Pervasive 
Developmental Disorders-Not Otherwise Specified (PDD-NOS) all share similar symptoms. 
Most of these disorders fall under the “umbrella” of ASD also known as pervasive 
developmental disorders (figure 1.1) 
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Figure 1.1: ASD umbrella (Connecticut Autism Spectrum Resource Centre, 2012)  
Rett’s syndrome (RS): Rett’s syndrome like Autism is a “severe neuro-developmental 
disorder that contributes significantly to severe intellectual disability” (Weaving et al., 2005). 
This syndrome was first described in 1983 and unlike autism, only occurred in females. This 
disorder showed unusually similar in terms of the clinical presentation of loss of motor skills, 
ataxia, and acquired microcephaly (Weaving et al., 2005). Typical features of RS are early 
onset at the ages of 6-18 months of age followed by normal development. It is caused by a 
mutation in the gene, MECP2 which encodes the methyl-CgP-binding protein and it is an X-
linked dominant disorder that affects the mechanisms of synaptic development (Armstrong et 
al., 1995, Percy, 2001). 
 
Fragile X Syndrome (FraX): Even though this disorder does not fall under the spectrum as 
indicated in figure 1.1, it still shares similarities with autism. FraX is presently regarded the 
most related cause of inherited mental retardation (Kaufmann et al., 2004), and is the 
expansion of a CGG mutation within the 5’ un-translated region of the FMR1 gene, 
depending on how many repeats are present. The affected alleles are classed as 1: normal of 
5-40 repeats; 2: intermediate/gray zone  of 45-54 repeats; 3: permutation of 55-200 repeats 
and 4: full mutation greater than 200 repeats (Maddalena et al., 2001). Individuals that have a 
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full mutation have cognitive impairment and behavioral abnormalities (Kaufmann et al., 
2004). 
 
Schizophrenia: Almost exactly a century ago patients with autism was diagnosed as 
schizophrenic (Bleuler, 1911). It is suggested to be the most disturbing form of psychiatric 
illnesses (Luhrmann, 2007). It presents consistently with a combination of different groups of 
symptoms starting with psychosis, progressing to emotional withdrawal ending with 
cognitive dysfunction. In recent research a clear distinction has been made between these 
disorders where autism appears during early childhood development and schizophrenia would 
present during early adulthood. Furthermore typical symptoms in schizophrenia would 
include hallucinations and delusions, which are rarely observed in autism (The University of 
Texas at Dallas News Center, 2012). Other differences separating autism from schizophrenia 
were familial backgrounds and differential treatment responses (Meyer et al., 2011).  
Regardless of these differences, overlapping of symptoms are strong between the two 
disorders on a behavioral level which includes the impairment of social interaction and 
cognition. Other symptoms observed between both autism and schizophrenia include the 
“disruption of emotional processing and sensorimotor gating and impairments of executive 
functions” (Rapin and Tuchman, 2008, Cheung et al., 2010, Meyer et al., 2011).   
 
Asperger’s: Asperger’s syndrome (AS) were described by a pediatrician Mr. H. Asperger in 
1944, who studied children exerting problematic social adaptation and communication skills 
(Todorov and Arnaoudova, 2012). Autism and Asperger’s has been considered as highly 
related disorders as most symptoms are clinically indifferent making diagnosis between them 
difficult (Sanders, 2009, Todorov and Arnaoudova, 2012). Both disorders appear with 
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“distinct verbal styles, motor signs, emotion perception and pragmatic reasoning” (Yu et al., 
2011). Distinguishing between the two however can be observed by the lack of clinically 
significant delay in cognitive development and language and the appearance observed only 
after the age of 3 years in autism and not in AS (Todorov and Arnaoudova, 2012). 
 
1.3. Prevalence of autism 
In the 1900’s in the USA it was proposed that metal preservatives used in medicines and 
vaccines caused autism.  In the 1960’s and 1970’s the incidence of this disorder were 
reported as no more than 5 in every 10 000 (Gillberg et al., 1991, Newschaffer et al., 2007) 
and in the 1980’s of ~10 in 10 000. In the 1990’s it was reported to range from 5 in 10 000 to 
72 in 10 000 (Sponheim and Skjeldal, 1998, Kadesjö et al., 1999, Newschaffer et al., 2007). 
The variation of the prevalence of autism became indicative of the increased awareness or 
information within communities. Up until 2007, surveys still showed increases of the 
incidence and variations amongst population. The incidence increased to 110 in 10 000 in a 
British report in a population of 55 000, giving rise to urgency for investigating autism, 
(Baird et al., 2006, Newschaffer et al., 2007). Based on studies conducted in different sites of 
the USA, the current prevalence of ASD is estimated to be one in 150 to one in 91 individuals 
with a male-to-female ratio of 4:1 (Kogan et al., 2009, Curtin et al., 2010). These statistics 
are consistent with the prevalent rates reported in other countries such as Europe and Asia, 
however some of the results for prevalence estimates are higher (Kogan et al., 2009, Boyle et 
al., 2011, Kim et al., 2011). Based on the evidence reviewed by Elsabbagh et al., (2012) 
median of worldwide prevalence estimates of ASDs is 62/10 000 (Elsabbagh et al., 2012). In 
China a prevalence rate of autism of 2.38/10,000 was observed, but this was based on a data 
set derived from only disabled children affected with the disorder (Li et al., 2011). Many 
children in SA remain undiagnosed or untreated due to lack of awareness among SA 
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communities. It has also been revealed that the knowledge for ASD awareness are lacking 
and that in the last decade only twelve scientific papers have been publish on ASD in Africa 
(Bakare and Munir, 2011). A total of only two papers shed light on the epidemiology and 
prevalence of autism in African countries. However these papers only shed light on the 
prevalence in Egyptian (33.6%) and in Tunisian (11.5%) population for autism (Seif Eldin et 
al., 2008, Bakare and Munir, 2011). 
 
There are no diagnostic or molecular tests for autism and cases have only been characterized 
on basis of behavior and social development amongst individuals by a qualified psychologist. 
It is reported that ASD is more prevalent in males with ratios of 4: 1 (male: female) for 
classic autism whereas Asperger syndrome observes higher ratios with 11:1 males to female 
(Baron-Cohen et al., 2011). The reasons for this observation continue to be blurry although it 
has been reported that the male bias for autism is thought to be caused by a hormonal 
perturbation during pregnancy with regards to genetic control and may be linked to 
development in the brain and immune systems. These events may thus overlap between 
autism and autoimmunity in determining male sex bias and may thus provide a link or 
evidence of etiology among autism (Becker, 2012). 
 
1.4.Causes of autism   
Autism is a neurological disorder which implicates the central nervous system (CNS). The 
CNS is composed of the brain, a very complex organ that regulates the motor- and 
neurological aspects of an individual and the spinal cord. The spinal cord harbors the stem of 
the neuro-systems and transmits messages from the brain to the extending body and as well 
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as receiving messages from extended body appendages. Since its first case report, the precise 
cause for this disorder is still elusive; etiology is multifactorial, which suggests a strong 
genetic foundation as well as an environmental component. Studies of genetic and 
environmental factors have provided some clues to elucidate the intricate pathogenesis of this 
disorder (Benvenuto et al., 2013). 
 
1.4.1. Environmental Factors 
Environmental factors are defined as those factors external to the individual, chemicals, 
drugs, light and temperature, food sources both biotic and abiotic. Foll and Giaggotti (2006) 
showed that a simulation could be used to identify the effects of environmental factors both 
biotic and abiotic on genetic variability and structuring and the likelihood of these factors 
having a genetic impact on generations or populations under various conditions. The most 
common environmental factors implicated in autism include chemical and drug influences. 
 
Chemical influences- Mercury poisoning: From the period of 1890 to 1950, a number of 
children suffered from a disease named Acrodynia (also known as pink disease) which had a 
fatality of  20% , (Initiative, 2005). Acrodynia is observed by the symptoms of alterations in 
temperament and skin, neurologic indicators, tachycardia, and stomatitis (Bjørklund, 1995). 
Warkany and Hubbard (1953) demonstrated that mercury was a causative agent because 25 
out of 28 sufferers had mercury poisoning. It was illustrated that the teething powders used 
on infants had mercuric chloride as the active agent (Bjørklund, 1995). It was also observed 
that among the individuals who were exposed to the teething powders showed symptoms 
similar to that of autism. To date research has shown that mercury is highly neurotoxic, 
especially during brain development (Costa et al., 2004, Davidson et al., 2004). 
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A survey done by the National Health and Nutrition Examination Survey has found that 
females ingesting seafood on a regular basis tend to have high levels of mercury in their 
blood system, as opposed to females who do not ingest seafood regularly, and that this places 
the infants carried by them at risk for neurological damage (Mahaffey et al., 2004). 
Thimerosal is a mercury based preservative used in various vaccines (Miles, 2011). The 
underlying mechanisms in mercury induced toxicity are still unknown. Some studies have 
reported that methyl mercury can easily cross blood-brain barriers and accumulate in the 
brain at high concentrations (Clarkson and Magos, 2006). Methyl mercury has also been 
reported to have interactions with a very broad range of cellular targets which results in 
multiple cellular function disruptions (Farina et al., 2011). 
 
It has thus  been proposed that the increase of autism might have been caused by the 
worldwide increased exposure of mercury through seafood’s, fish and industrial sources and 
through increased exposure of thimerosal (Mutter et al., 2005). 
 
Drug influences- Prenatal stage: The prenatal stage for a newborn is the most critical state 
because brain development is at its most vital stage of the maturation process. The 
developing brain is at risk during this time in the womb as it can be subjected to damage and 
underdevelopment when fed with harmful addictive substances such as alcohol, cocaine and 
other chemicals, as this has been  observed with fetal alcohol syndrome, and also in the 
etiology of Autism (Baird et al., 2003).  
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Prenatal exposure to ethanol has been demonstrated to be associated and considered a risk 
factor for the development of behavioral abnormalities in children (Middleton et al., 2012). It 
has been demonstrated that ethanol exposure affects the amygdala and ventral striatum 
causing deficits in social behavior in a way that is time, age and gender dependent (Mooney 
and Miller, 2001). The prenatal exposure to cocaine in rats was demonstrated to have an 
induced alteration in the brain serotonin system. The drug cocaine is an addictive chemical 
and causes differential changes in neuroendocrine responses (Carrasco et al., 2006). 
Serotonin has been implicated in all the different behavioral types and perturbations of this 
system and can elicit alterations to those behavioral types (Frazer and Hensler, 1999).  
 
The use of antibiotics during pregnancy has also been reported to be a strong risk factor for 
autism in the developing brain. A study showed twofold increased risk of infantile autism 
when mothers experienced an immune activation during the pregnancy (Atladóttir et al., 
2012). Another chemical or drug that poses risk includes Valproic acid (VPA). VPA is a 
known teratogen and when exposed during pregnancy has demonstrated to cause a threefold 
increase in the rate of developmental problem which are often observed with autism (Ornoy, 
2009). An animal model induced during prenatal exposure to VPA has thus been proposed to 
study autism. This study demonstrated numerous behavioral abnormalities in the VPA rats 
(Bambini-Junior et al., 2011). Another study also showed that VPA exposure rats showed 
several behavioral abnormalities which are also found in autism (Mychasiuk et al., 2012). 
 
1.4.2. Genetic factors 
Genetics factors play a predominant role in autism pathogenesis. Several studies have given 
convincing results for the involvement of genetic factors in the development of autism 
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(Folstein and Rutter, 1988, Bailey et al., 1995, Korvatska et al., 2002, Lauritsen et al., 2005, 
Waltes et al., 2014). It has been reported that gene mutations, deletion, substitutions or 
additions have resulted in diseases and disorders. A copy-number change by definition is the 
deletion or duplication of a piece of DNA and can range from a kilo-base pair to mega-base 
pairs and or could even include the whole chromosome (Feero et al., 2012). Deletions may be 
heterozygous, in which case one of the usual two copies is missing; homozygous, when both 
copies are missing; or hemizygous (e.g., X-chromosome deletions in a male patient) (Feero et 
al., 2012).  
 
Twin studies: Studies done on autistic twins and families have shown that it is heritable and 
that the recurrent risk of PDD in siblings of children with autism is 2 to 8% (Muhle et al., 
2004, Chaste and Leboyer, 2012) and is ~50 to 100 times greater than individuals with no 
history of the disorders or minor forms of it (Bolton et al., 1994, Philippe et al., 1999). It was 
demonstrated that twins who share 100% identical genes, (monozygotic (MZ)) in comparison 
to twins who only share 50% identical genes, (dizygotic (DZ)) ten to have a much higher 
(about 82%) occurrence for this disorder than the other (about 10%). The first genome-wide 
scans for genes implicated in the etiology for autism implicated numerous chromosomes 
which included chromosomes 4, 5, 6, 7,10, 16, 19, 22 (Philippe et al., 1999). Many more 
chromosomes have been identified since, however the most popular implicated would be 
chromosome 7. This chromosome has been labeled as a “hotspot” for genes of interest as it 
harbors a number of candidate genes table 1.1. 
 
Chromosome 5 has also been previously associated with autism (Gillberg, 1998) and is even 
more significant since two genes Cadherin 9 (CDH9) and Cadherin10 (CDH10) have been 
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implicated in the etiology of autism (Wang et al., 2009, Prandini et al., 2012). These genes 
transcribe adhesion peptides that are very important for cell-cell signaling expressed in the 
frontal cortex, associated with autism (Flintoft, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
   
Table1.1: Genes previously associated with ASD 
 
Chromosome Genes Gene name Reference 
2 SLC25A12 Solute Carrier Family 5 member 12 
(Ramoz et al., 
2004) 
5 CDH10 Cadherin gene 10 type II 
(Prandini et al., 
2012) 
6 GL01 Glyoxalase 
(Junaid et al., 
2004) 
6 GRIK2 Glutamate receptor Inotropic kainite 2 (Kim et al., 2007) 
7 HOXA1 Homeobox A1 
(Ingram et al., 
2000) 
7 RELN Reelin 
(Sharma et al., 
2013) 
7 WNT2 
Protein Wnt-2 precursor  
 
(Wassink et al., 
2001) 
7 FOXP2 Forkhead-box Protein P2 (Li et al., 2005) 
7 EN2 Engrailed homeobox 2  
(Gharani et al., 
2004) 
7 UBE2H Ubiquitin-conjugating enzyme E2H 
(Vourc'h et al., 
2003) 
10 PTEN Phosphatase and tensin homolog 
(Butler et al., 
2005) 
11 HRAS Harvey rat sarcoma viral oncogene homolog 
(Comings et al., 
1996) 
12 AVPR1A Arginine vasopressin receptor 1A 
(Wassink et al., 
2004) 
12 CACNA1C 
Calcium channel, Voltage-dependant, L type alpha 
1C subunit 
(Lu et al., 2012) 
15 UBE3A Ubiquitin protein ligase E3A 
(Glessner et al., 
2009) 
15 ATP10C ATPase, Class V, type 10C 
(Herzing et al., 
2001) 
15 GABRB3 
Gamma-aminobutyric acid (GABA) A receptor, 
subunit beta 3 
(Mccauley et al., 
2004) 
17 SLC6A4 
Solute carrier family 6 (neurotransmitter 
transporter, serotonin), member 4 
(Sutcliffe et al., 
2005) 
17 NF1 Neurofibromin 1 
(Marui et al., 
2004) 
17 CACNA1G 
Calcium channel, voltage-dependant, T type, alpha 
1G subunit  
(Lu et al., 2012) 
19 APOE2 Apolipoprotein E 
(Persico et al., 
2004) 
20 ADA Adenosine deaminase, RNA-specific 
(Bottini et al., 
2001) 
22 SHANK3 Shank 3 
(Yasuda et al., 
2011) 
22 CACNA1I 
Calcium channel,voltage-dependant, T type, alpha 
1I subunit 
(Lu et al., 2012) 
X NLGN3 Neuroligin 3 
(Jamain et al., 
2003) 
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1.5.Diagnosis and Treatment  
Thus far, autism has been diagnosed only by behavioral patterns by psychologists or 
psychiatrists. It is observed in children between the ages of 2-3 years and it was noted that the 
child does not socially interact easily or at all with peers or family members. Common 
features that may suggest that a child may be autistic includes a) lack of a social smile and b) 
appropriate facial expressions c) poor or no  attention, d) impaired social interactions e) 
preference to aloneness and f) ignoring people (Baird et al., 2003). A clinician would screen 
the child using the DSM-IV manual and other tests to confirm the diagnosis. 
 
There is no known medical cure for these disorder only treatments (Lee and Kong, 2012). 
Individuals with autism who tend to have erratic behavior are medicated to reduce the risk of 
harming themselves or others. The medication previously used includes a selection of typical 
anti-psychotic, atypical anti-psychotics, antidepressants, stimulants, anti-convulsants and 
others. Respiredone is a commonly used atypical antipsychotic but others include Olanzapine 
and Clozapine (Broadstock and Doughty, 2003). Commonly used treatments are dietary, 
modifications, music therapy  and many other types of behavioral therapy, which have been 
used to calm an autistic individual (Grant, 2011). The efficacy however is quite limited from 
one to another because there is a huge difference in severity and symptoms (Lee and Kong, 
2012). Sometimes it becomes frustrating for the families to deal with the behavior changes, 
and attempt to find solutions for example, a case recently reported the plight of a father who 
explored the idea of using roundworms. The reason being that roundworm modulates the 
inflammatory immune responses, which alleviated his son’s disruptive behavior (Grant, 
2011). Although this may be a breakthrough it still does not become a cure due to the diverse 
nature of autism. 
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1.6.Association studies 
Genetic association studies or association studies are investigated in order to find the 
correlation between a disease status and a genetic variation that result in the identification of 
candidate genes or genome regions responsible for that disease (Lewis and Knight, 2012). 
These studies are conducted by determining the genetic variants like single nucleotide 
polymorphisms (SNPs), copy number variants (CNVs) and structural variants present in 
different groups. The genome-wide association method has been scientifically convincing 
and has underlined numerous and novel biological pathways in disease processes (Knight, 
2009). The present study conducted aimed at incorporating this method to establish and 
determine the variation of selected markers or SNPs in the autistic SA population.   
 
1.6.1. Single nucleotide polymorphisms (SNPs)  
The human has 23 chromosomes that constitute its genome. It is large and vast and has been 
studied extensively for decades in the hope of understanding how the human species operate 
or sustain itself on a molecular level. SNPs by definition, are “a source of variance in a 
genome, a single base mutation in DNA and are the most simple and common source of 
genetic poly-morphism in the human genome” (Smith, 2002). When cells divide and multiply 
the genome is copied as well and during this process random mutations occur; deletion, 
substitution or addition of nucleotides. These mutations can then be transferred from 
generation to generation that allows for its tracking. Since the mutation is in the direct path of 
DNA sequence that is related to protein, the change in sequence thus results in change in 
transcript and can results either in the transcription of a faulty or a less active protein. 
Research has shown that differences on the DNA level (inherited), adds to phenotypic 
variations, affecting the anthropometric characteristics of an individual, and the risk of 
disease  (Sachidanandam et al., 2001). The frequency of variations occurring between 
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members of a species or between paired chromosomes in an individual is >1% and provides 
geneticists with a powerful tool for the study of human medical genetics (Wang et al., 2008). 
SNPs are the most frequent type of variation in the human genome and thus yields as a very 
powerful tool and marker for genetic studies (Wang et al., 1998). 
 
1.6.2. SNPs studies on autism 
Due to the high frequency of SNPs in the human genome it has created an opportunity for 
researchers to track and establish genetic variations on a large scale in cohort’s studies. 
Genome wide association studies (GWAS) have investigated thousands of SNPs in thousands 
of individuals and have thus been able to implicate common genetic variants in more than 80 
human diseases (Hindorff et al., 2009).  These results have generated large amounts of data 
extracted from assayed SNPs that rendered very significant insights with respect to 
associations made between loci and common diseases that may not have previously been 
shown to share etiological pathways. Other benefits were the associations made in 
chromosomal regions or spaces that were considered to be deprived of functional genes or 
genetic loci, (Manolio et al., 2008, Hindorff et al., 2009). These studies have been very useful 
by categorizing key characteristics of observed associations and complex human disorders 
(Hindorff et al., 2009). This has allowed the assessment of autism, and a few genes have been 
successfully implicated by scanning of the genome. Some of these genes of interest include 
Engrailed Homeobox 2 (EN2), Serotonin (SERT), Reelin (RELN), and Cadherin 10 type II 
(CDH10) (Benayed et al., 2009, Wang et al., 2009, Gadow et al., 2013, Sharma et al., 2013). 
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Engrailed Homeobox 2 gene (EN2): The Engrailed Homeobox 2 transcription factor came to 
light when certain similarities were observed with regards to the development of the 
cerebellum in mouse brains. The EN2 gene is located on the human chromosome 7q36 and 
has been linked to ASD (Benayed et al., 2005). This location has been under investigation as 
it seemed to house other interesting genes that have important roles in language and speech 
development, regulation of brain cell formations and primary development of bodily organs 
and particularly the nervous system. EN2 gene is also responsible for the development of the 
cerebellum in humans when comparative studies were done between mice and an autistic 
human sample. A study done by Gharani (2004) and coworkers focus on four SNPs for the 
EN2 gene. The results for that study showed that two intronic SNPs, rs1861972 (P=0.0018) 
and rs1861973 (P = 0.0003) had strong signal for autism with a haplotype p value of 
0.000005 (Gharani et al., 2004). In addition, Benayed and coworkers (2005) reinforced the 
significance of the SNPS and demonstrated in a population-attributable risk test, that the risk 
allele contributed to 40% of ASD cases in the general population.  
 
Serotonin gene (SERT): The SERT gene (5-HTT) encodes for a serotonin transporter, which 
is “involved in the pre-synaptic reuptake of serotonin to terminate and modulate the 
serotonergic neurotransmission” (Nakamura et al., 2000). The dysfunction of this  protein 
have been implicated in other psychiatric disorders which includes anxiety, depression and 
more over is mainly focused on mood change and behavior which are co-morbid symptoms 
of ASD (Nakamura et al.,2000). In recent studies association of this gene to autism is 
strengthening in SNP studies. Gadow and coworkers (2013) reported that the SNP rs25531 
for the SERT gene may modulate severity of ADHD and ASD symptoms for subjects with 
ASD. 
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Reelin gene (RELN): The RELN gene located on the distal long arm of chromosome 7 has 
also been associated with ASD primarily because of its role in brain development. It has been 
reported that the RELN protein plays a pivotal role in the migration of several neuronal cell 
types and in the development of neural connections (Skaar et al., 2004). It has been observed 
that RELN mRNA and protein levels are significantly reduced in multiple brain areas of 
patients with schizophrenia and bipolar disorder with psychosis (Impagnatiello et al., 1998, 
Guidotti et al., 2000, Skaar et al., 2004).  It is for this reason that it was considered as a 
candidate gene in the pathogenesis of ASD as these other psychiatric disorders are all co-
morbid with ASD and their symptoms all fall under the same spectrum of complex disorders. 
Sharma and coworkers (2013) considered the potential implications of this gene to autism 
and conducted an association study in SA. A significant association of the intronic SNP 
(rs736707) with autism was observed in the SA population.  
 
Cadherin 10 type II gene (CDH10): Similarly like the other candidate genes, CDH10 is a 
gene that plays important roles in brain development, in the early stages of fetal growth. It 
has been under investigations in a GWAS that resulted in the detection of  a very significant 
SNP (rs4307059) found between the inter-genic regions of genes CDH10 on chromosome 5 
(Pourcain et al., 2010). This gene encodes a calcium dependent cell surface glycoprotein that 
is involved in cell adhesions and cell signaling during early stages of development. The gene 
CDH10 form part of a subgroup of the family known as classic cadherins type II that mediate 
strong cell-cell homophilic interactions and are localized to the nervous systems and 
functions for regionalization of the brain, formation, maintenance and the plasticity of neural 
circuits (Redies and Takeichi, 1996, Hirano et al., 2003, Takeichi, 2007, Hulpiau and Van 
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Roy, 2009, Etzrodt et al., 2009). Two individual association studies investigated this gene for 
associations in different population settings. In a European study, the cohorts were genotyped 
using an Illumina HumanHap550 BeadChip which contained up to 550,000 SNP markers. 
Only six SNPS showed strong signals for association of which the most significant SNP was 
SNP rs4307059 with a P value of 3.4 X10
-8
 (Wang et al., 2009). This same result was 
observed in an family cohorts specific for Italian ancestry. The SNPS rs4307059 displayed 
strong association once again with P values of 0.0017 (Prandini et al., 2012).        
 
1.7.Application of proteomics in autism research  
Proteomics is the comprehensive investigation and characterization of proteins, through 
biochemical methods (Pandey and Mann, 2000). This method functions on the concept of 
proteins being the down-stream products of gene expression which are the active agents in 
cells and as a results is useful in the drug development arena and therein diagnostics (Pandey 
and Mann, 2000).  
Proteomics is defined as the study of a proteome, the total protein content of one cell or all 
cells of an organism where cells are from the bodily fluids e.g. blood/urine/sweat or tissues or 
organs and bodily parts (Dihazi and Müller, 2007). This term was originally established by 
Dr. Marc Wilkins of the Macquarie University, a PhD student at the time, denoting 
proteomics as the protein quota for a known genome (Verrills, 2006). 
 
It is a study that investigates isolated proteins and is aimed at identifying proteins that may 
have or cause un-welcomed effects within a system. Figure 1.2 demonstrates the relationship 
between DNA and proteins. Proteins are the downstream results of genes and their expression 
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and thus have very important roles within its system (Genetics Home reference, 2011). Since 
a large amount of DNA sequences have been investigated and collectively accumulated in 
databases, it has been observed by researchers that these enormous loads of data on complete 
sequences does not suffice in understanding basic biological operations, and therefore 
directed their attention towards proteins as there are no strict linear link or path between 
genes and their resulting products-proteins (Pandey and Mann, 2000). Functional genomics 
thus focuses on the characterizations of sub-cellular interactions of proteins and 
macromolecular complexity of cellular organisms (Monteoliva and Albar, 2004). The human 
genome has successfully been sequenced in 2003 with 600 000 DNA base pairs, about 20 
000-25 000 genes all located on 24 chromosomes (The human genome project, 2003). 
.  
Figure 1.2: Genes to proteins (The human genome project, 2003). 
 
The proteome of an organism is very unique as the protein profile tends to change in response 
to different stimuli, both extra and intra cellular stresses including, cell cycles, temperature 
etc., because of this reason, more researchers gaze towards a proteomic approach in 
molecular science (Dihazi and Müller, 2007). This approach has become the leading 
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technology in understanding various conditions and physiological states of different tissues in 
both prokaryotes and eukaryotes (Oh et al., 2005). There are three main areas in proteomics, 
one: Protein micro-characterizations two: differential displays and three: Protein-protein 
interactions which focus on the identification for proteins and their post translational 
modifications, comparisons of protein levels and their interactions respectively (Dihazi and 
Müller, 2007). There are three areas which one can pursue the investigation of proteins viz 
expressional, structural and functional proteomics (figure 1.3). Each method harboring 
different ways of isolating, identifying and analyzing a sample. 
  
Figure 1.3: Proteomic studies and approaches (Adapted from Chandramouli and Qian, 2009). 
 
 
 
 
 
23 
   
Depending on the what the end result should provide, one can  utilize a “gel-based and non-
gel-based approach” by which the proteins can be characterized, the one deals in resolving 
proteins by 2 Dimensional Poly Acrylamide Gel Electrophoresis, (2D-PAGE) and Mass 
Spectrophotometry (MS) that operates by investigating the mass to charge ratio of the target 
protein, e.g. MALDI- TOF. The other involves the processing of the isolated protein sample 
through high thorough-put technology including Multi-Dimensional Protein Identification 
Technology (MUDPIT), Liquid Chromatography (LC), and the combination of Liquid 
Chromatography to Tandem mass spectrometry (MS/MS) but not limiting the methods to it-
self.  
 
1.7.1. Gel-based and non-gel based 
Gel based proteomics have been frequently used due to the fact that it allows for differential 
expression analysis and thus allows for discrimination of protein expressions between healthy 
and otherwise diseased/induced or experimental sample sets. It incorporates the display of 
proteins on what is called acrylamide gels for simple visualization and mapping differences 
in a 2nd dimension (Monteoliva and Albar, 2004). Primarily proteins are separated by its 
molecular mass with one dimensional electrophoresis (1DE). Two-dimensional 
electrophoresis (2DE) involves the separation by Iso-electric focusing (IEF) first, then 
separation by molecular mass (Verrills, 2006). The proteins are separated according to their 
net charge (pI) on a pH strip in a horizontal direction, followed by a separation in the second 
dimension according to molecular mass vertically on an acrylamide gel and is very useful 
since it allows for reproducibility (Verrills, 2006). The 2D separation is usually done on a 
poly-acrylamide matrix and has variations or different mediums through which it can be done 
and the protein profile is visualized using a selective stain or dye such as Coomassie brilliant 
blue R-250 stain. 
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Complex protein mixtures can either be separated on “native gels” non-denaturing gels, 
Sodium Dodecyl Sulfate Poly acrylamide gels (SDS-PAGE), also known as denaturing gels, 
or be subjected to 2 dimensional difference gel electrophoresis (2DIGE). The difference 
between the three types of gels is that with native gels, even though used extensively for 
complex mixtures, separates the proteins with intact quaternary structure, size and charge, the 
SDS gels, does the opposite and is preferred method, since it removes the charge and 
linearizes the proteins before separation and thus separated according to the size or length of 
the proteins. The difference between these two methods and 2DIGE is the simple addition or 
labeling of proteins with radioactive isotopes. 
Each method has its advantages and disadvantages which is dependent on what the aim of a 
study would be. While Gel- based methods are perfect for biomarker discovery it also allows 
for separation of large numbers of proteins and peptides and comparative analysis of two 
sample sets. Whereas gel-free methods are advantages for analysis of samples with very little 
quantities and are much more automated than the laborious gel based method. Table 1.2 
outlines the differences between these two methods, their benefits and drawbacks.  
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Table 1.2: Gel based and non-gel based methods compared (Modified from Dihazi and Műller, 2007). 
 Gel-based methods Gel free methods 
 2 Dimensional  Gel 
Electrophoresis (2D 
electrophoresis) 
 
Difference Gel 
Electrophoresis 
(DIGE) 
Surface Enhanced 
Laser Desorption 
Ionization (SELDI) 
Liquid Chromatography 
–Mass Spectrometry 
(LC-MS) 
Capillary Electrophoresis-Mass 
spectrometry (CE-MS) 
Advantages -Separation of large 
number of proteins 
- Easy biomarker 
identification 
- Allows for 
quantification 
-Separation of both 
experimental and 
control sample mix 
on single gel 
-Less amount of 
protein sample 
required 
-Use of internal 
standard possible 
-Quantification 
possible 
-Automated 
-High throughput 
analysis 
-Less protein sample 
required 
 
-Quantification possible 
-Automated 
-High throughput 
analysis 
-Less protein sample 
required 
-Sample fractionation 
LC 
-Quantification possible 
-Automated 
-High throughput analysis 
-Less protein sample required 
- Sample fractionation CE 
 
Disadvantages -Requires large 
sample amounts 
-Lack of automation 
-limitation for large 
and small proteins 
-Loss of Hydrophobic 
proteins 
-Not useful screening 
tool 
-Not  reproducible 
-Laborious 
 
-Lack of automation 
-limitation for large 
and small proteins 
-Loss of 
Hydrophobic 
proteins 
-Expensive 
-Laborious 
-Drawbacks in 
detecting low 
abundance proteins 
-Lack  detection of 
high molecular weight 
proteins 
-Problematic protein 
and post translational 
modification 
identifications 
-Protein fractionation  
required 
-Drawbacks in detecting 
low abundance proteins 
-Lack detection of high 
molecular proteins 
 
-Drawbacks in detecting low 
abundance proteins 
-Lack  detection of high molecular 
weight proteins 
-Proteins identification problematic 
-Deliver complex patterns 
-Pattern recognition not a single 
biomarker 
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1.7.2. Mass Spectrometry Technology (MS)  
The identification of molecules, peptides, ions of any small or micro sized level has great 
importance when it comes to biological research. Mass Spectrometry or MS is a technology 
that identifies any micro molecule, compounds through the determination of the physical 
mass to particle charge ratio (m/z) by  means of ionizing the molecules and then subjecting it 
into an electric field for detection (Proteomics Shared Research, 2011). Figure 1.4 shows the 
basic flow for mass spectrometry analysis. A sample is ionized in a chamber, followed by 
sorting or separations based on mass and lastly detection chamber that picks up each peptide 
and relates the result. 
 
 
Figure 1.4: Mass spectrophotometer basic components, an ion source, mass analyzer and a 
detector (Aebersold and Mann, 2003).  
There are various ways of ionizing a sample, of which two, Electrospray ionization (ESI)  
and Matrix Assisted Laser Desorption/Ionization (MALDI) is most commonly used, others 
includes, chemical ionization (CI), Atmospheric Pressure (APCI), Electron Impact (EI), Fast 
Atom Bombardment (FAB), Field Desorption/Field Ionization (FD/FI) and Thermospray 
Ionization (TI)  (Proteomics Research Shared, 2011). The basic MS consists of an ion source, 
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a mass analyzer and the detector (Aebersold and Mann, 2003). The sample is ionized the 
analyzer measures or determined the  m/z value and the detector registers the numbers of ions 
at each m/z value that  appears as peaks in a spectrum (Aebersold and Mann 2003). 
Electrospray is a method that incorporates the streaming of liquid containing the sample of 
interest and applying an electrical charge to it, thereby ionizing it (Proteomic shared research, 
2011). MALDI utilizes a laser which ionizes and vaporizes the sample, followed by a MS 
analysis. Likewise, as there are different Ion sources, there are different analyzers and 
detectors. The most common analyzers include Quadruples, Time-of-Flight Magnetic sectors 
and more while different detectors would include Electron multiplier and Faraday cup. The 
combination of these technologies thus renders potential information data or results and 
therefore the method will be employed in this study. 
 
The methods employed in this thesis were used in hope of determining genetic variants that 
influences the outward phenotype amongst individuals, which includes association studies 
and proteomic studies. The association studies used single nucleotide polymorphism (SNPs) 
of a specific gene and the probability was determined and the probability of their association 
was calculated in the SA autistic population. In the proteomic study urine proteins were 
isolated and evaluated as potential biomarkers in SA African autistic individuals.  
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1.8.Aims of project 
The aims of this project are twofold: 
1.  To study the association of SNPs rs4307059 and rs4327572 for the CDH10 gene in 
the healthy and autistic SA population.  
2. To generate a proteome profile for African autistic individuals that could shed light on 
the differential expression of proteins between SA autistic and a healthy group.  
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Chapter 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
   
Abstract 
Autism spectrum disorders (ASD) is a complex behavioral disorder that are primarily of 
genetic origin (Schanen, 2006). The aim of part of this study was to investigate genetic 
association of SNPs rs4307059 and rs4327572 for the CDH10 gene with autism in the SA 
population. A non-significant association was observed between these SNPs and autism 
status in SA population. The Chi-square test was used to study the association of these SNPs. 
The TT, CT, CC genotypes for rs4307059 had prevalence of 71.2%, 20.8% and 8% for the 
healthy subjects while the autistic population had distribution percentages of 65.4%, 28.7% 
and 5.9%. The rs4327573 genotype percentages for CC, CT and TT were 1.9%, 26.8 % and 
71.3 % for healthy SA population compared to the autistic population percentages of 4.2 %, 
27.8% and 68.1%. There were no significant association between both SNPs (rs4307059 and 
rs4327572) and the status of autism in the South African population.  
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Genetics of autism in a SA 
population 
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2. Genetics of autism 
2.1 SNP studies on autism in South Africa (SA) 
An abundant amount of SNP association studies have been generated from SNP data of 
which most have been investigated in other populations (Manolio et al., 2008, Hindorff et al., 
2009). The importance of identifying or making these associations of genes relates to the 
etiology of the ASD disorder. Predominantly the genetics of the SA population is diverse and 
requires these types of studies to exclude or include genes in the etiology of ASD in SA. The 
CDH10 gene in particular has recently been implicated in ASD in the broader European and 
Italian population with strong association (Wang et al., 2009; Prandini et al., 2012). 
 
2.1.1 The Cadherin 10 type 2 gene (CDH10)  
The cadherins comprise a family of transmembrane glycoproteins (Juliano, 2002). The 
members of this family are categorized according to specificity of binding. Predominantly 
cadherins are homophilic and have roles in adhesion; other members may be heterophilic and 
have very poor binding (Redies and Takeichi, 1996). These molecules mediate calcium-
dependent cell-cell adhesion rendering them very important for cell-cell interactions (Suzuki 
et al., 1991). Up until 1991, only three types of cadherins had been characterized namely 
Epithelial (E)-, Neural (N)-, and Plasmental (P)-cadherin (Suzuki et al., 1991). It’s been 
nearly three decades since the identification of this molecule and now there are more than 20 
members that comprise this family. Cadherins are classed based on molecular structure into 
Classical Cadherins (type I and II), Desmosomal Cadherins, Protocadherins and others 
(Redies and Takeichi., 1996). Table 2.1 is a list of cadherins members identified in the human 
genome. 
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Table 2.1: Cadherins members found in the human genome (Modified from Pȍtter et al., 
1999)  
Name 
a
 Symbol 
b
 
Locus 
c
 Main expression in  Type 
d
 
E-Cadherin, Uromodulin (mouse), L-CAM 
(chicken) 
CDH1 16q22.1 Epithelial I 
N-Cadherin  CDH2 18q11.2 Neuronal cells I 
P-Cadherin CDH3 16q22.1 Skin, prostate, placenta I 
R-Cadherin, cadherin-4 CDH4  Retina, brain I 
VE-Cadherin, cadherin-5 CDH5 16q22.1 Vascular endothelium, 
brain 
II 
K-Cadherin; cadherin-6 CDH6  Fetal kidney/brain II 
Cadherin-7 CDH7  Brain II 
Cadherin-8 CDH8  Brain II 
Cadherin-9, T1-cadherin CDH9  Brain II 
Cadherin-10 CDH10  Brain II 
OB-Cadherin, cadherin-11 
 (mouse, rat, chicken) 
CDH11 16q22.1 Osteoblasts, brain, 
testis, lung, placenta 
II 
Br-Cadherin, cadherin-12 CDH12 5p13-p14 Brain II 
H-Cadherin, cadherin-13, T-Cadherin (chicken, 
human) 
CDH13 16q24.2 Heart, brain, aorta O 
M-Cadherin, cadherin-15 CDH15 16q24.3 Muscle, brain I 
Ksp-Cadherin CDH16 16q21-q22 Kidney O 
HPT1, L1-cadherin (rat) CDH17 8q22.1 Liver, intestine O 
Cadherin-18, cadherin-14 CDH18  Brain II 
Pcdh1, protocadherin 42 PCDH1 5q31-33? Brain, melanoma cells PC 
Pcdh2, protocadherin 43 PCDH2 5q31-33? Brain, fibroblast PC 
BH-Protocadherin PCDH7 4p15 Brain, heart PC 
Desmoglein 1 DSG1 18q12.1 Skin D 
Desmoglein 2 DSG2 18q12.1 Epithelia D 
Desmoglein 3 DSG3 18q12.1 Skin D 
Desmocollin 1 DSC1 18q12.1 Skin D 
Desmocollin 2 DSC2 18q12.1 Epithelia D 
Desmocollin 3 DSC3 18q12.1 Skin D 
RET RET 10q11.2 Neuronal derived cells O 
hFAT FAT 4q34-q35 Epithelia, T-cell lines, 
Fibroblasts, 
keratinocytes 
O 
FIB1, FIB2, FIB3   Fibroblasts O 
ME1 to ME6   Melanoma cells, 
melanocytes 
O 
a
 Name of human cadherin or its species homologue 
b 
HGMW-approved gene symbol according to GenBank 
c
 Chromosomal location of the human gene 
d 
Five subgroups of cadherins: I, II classical type I and II, respectively; D, Desmosomal cadherins; PC 
Protocadherins;  O, Other related cadherins. 
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This family and its members still branches off into more subfamilies of which at least 80 
members have been shown to be expressed within a single mammalian species, of these 
includes classic cadherins (Pötter et al., 1999). Cadherins, the major groups, type II 
predominantly have been shown to be expressed in the brain in the frontal cortex region 
(Pötter et al., 1999).  
 
The brain is central to the central nervous system (CNS) and since autism is a “polygenic 
neurological disorder that affects the CNS” (Benayed et al., 2009), thus investigation of 
connections within the CNS, can lead to clarity on the pathogenesis of autism. This CNS is 
complex and highly organized neural networks that generate brain function (Yagi and 
Takeichi, 2000). Ultimately cadherins are synaptic components with roles in neuronal 
circuitry, synaptic junction formation and synaptic plasticity (Suzuki et al., 1997, Tang et al., 
1998, Honjo et al., 2000, Manabe et al., 2000, Tanaka et al., 2000, Yagi and Takeichi, 2000) 
and are known to act alongside catenins, which are polypeptide molecules that strictly bind to 
these synaptic components (figure 2.1). Catenins are cytoplasmic proteins composed of β-
catenins, α-catenins and p120-catenin. β-catenins binds to the tail of the cadherin molecule 
where it acts as an anchor for the α-catenins and p120- catenin binds to membrane region of 
the cadherin. These three molecules have functions of signal transducers, intracellular 
trafficking and regulating actin dynamics and lastly regulating cell locomotion (Niessen and 
Leckband, 2011). 
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Figure 2.1: Cadherin structure and localization in synaptic cell-to-cell adhesion junctions. 
The cadherin-catenin complex are composed of the cadherin molecule bound to β- and α-
catenins which aids binding to actin containing cytoskeleton (Juliano, 2002). 
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2.1.2 The genomic  and proteomic organization of CDH10 
CDH10 resides on chromosome 5 between locus regions 24,487,209 base pairs (bp) and 
24,645,087 bp. The CDH10 gene is 157.88kb in length and is found on the reverse strand of 
chromosome 5 and is conserved in other species such as primates (figure 2.2).  
 
 Figure 2.2 : Gene Ancestry and homology of cadherins (Ensemble, 2011) 
One of the closest species homologs to the human is the common house mouse, Mus 
musculus, (Not shown in the figure above) with associating roles like cell adhesion, plasma 
membrane calcium ion binding (The gene ontology, 2011). The gene is conserved between, 
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its genomic organization and is closely linked and conserved between family members of the 
cadherin family as some members may derive from 12 exons, other vary up to 16 exons 
(Yagi and Takeichi, 2000). Classic cadherins including CDH10 are highly conserved and has 
5 tandemly repeated extracellular domains that are interrupted by multiple introns while some 
protocadherins are not (Hatta et al., 1988, Gumbiner, 1996, Strehl et al., 1998, Wu and 
Maniatis, 1999).  
 
As previously mentioned, CDH10 type II is a classic cadherin  and is unique as it has up to 5 
conserved extracellular domains (EC domains) and  a single cytoplasmic domain, all 
connected by a transmembrane segment (Takeichi, 1990, Uemura, 1998, Wu and Maniatis, 
1999). The EC domains engage specific to homophilic molecules rendering its specificity, as 
it may only bind to other EC domains with similar motif structures (Nose et al., 1988, Wu 
and Maniatis, 1999) whereas the cytoplasmic domains renders the molecules to interact with 
β-Catenins in the plasma membrane that plays a pivotal role in “epithelial-mesenchymal 
transition during development” (Aberle et al., 1996, Wu and Maniatis, 1999). The EC 
domains separates cadherin members from each other as the amount of EC domains may vary 
due to negatively charged sequenced motifs (DXD, DRE, and DXNDNAPXF) that have roles 
in Ca
2+
 binding (Takeichi 1990, Yagi and Takeichi,2000). 
 
2.1.3 CDH10 function and expression 
CDH10, a cadherin, forms part of a multitude of cell-cell adhesion molecules that connects 
the most important cells required for brain signaling neurons. It is reported that synapses have 
physiological and adhesive functions and neurons communicates with each other through 
them (Yagi and Takeichi, 2000). Although found in synapses, cadherins and catenins have 
not been found to be present in the adherent junction zones of synapses yet appear in 
 
 
 
 
41 
   
surrounding areas (Yagi and Takeichi, 2000). These Cadherin and catenins complexes are 
aligned symmetrically over the pre- and postsynaptic plasma membrane  and tend to act as a 
kind of “lock-and- key component for regulating specific interneuronal connections, as 
hypothesized by Sperry (1963)” (Uchida et al., 1996, Yagi and Takeichi, 2000). 
 
Data on this gene’s expression is limited in comparison to other family members. The 
expression pattern for this gene has been investigated in other species such as chickens and 
rats. These studies monitored the CNV and the limbic system for gene expression whilst also 
studying the total RNA from different human samples (Kools et al., 1999, Liu et al., 2006). 
In a study conducted by Shimoyama et al., (2000), cDNA clones were sequenced for the 
CDH10 and CDH7 gene. Results of this study showed that for CDH10 and CDH7, the clones 
consisted of 3261 and 3060 nucleotides, respectively and that it shows very high homology of 
96 and 94% to chicken. The expression for the CDH family is both spatially and temporally 
regulated, and research found that these molecules indicate vital roles in the development of 
the vertebrate nervous system (Nakagawa and Takeichi, 1995, Radice et al., 1997, Lele et al., 
2002, Malicki et al., 2003, Masai et al., 2003, Liu et al., 2006).  Furthermore a test for cell-
cell binding activity showed that CDH10 not only associates with β-catenins but also with α-
catenins which confirms the cadherin-catenin complex (Shimoyama et al., 2000). 
 
It is clear that the gene is relative more expressed in the brain as reported by Kools et al., 
(1999).  An investigation of this protein’s RNA expression was observed in most of the brain-
derived tissues which are constantly monitored when doing studies on ASD as it is for the 
most part, the most effected body part in ASD (Kools et al., 1999). 
 
2.1.4 Genomic location of CDH10 
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CDH10 resides on chromosome 5 (figure. 2.4), “one of the largest chromosomes” in the 
human genome with numerous intra-chromosomal repetitions but consists of very few gene 
densities (Schmutz et al., 2004). A chromosome, 177.77 base pairs long that houses about 
923 gene loci and is associated with at least 80 human diseases and associated to 66 specific 
loci (Schmutz et al., 2004) (figure. 2.3). Most of these diseases are related to cancer, but also 
disorders of the mind (e.g.; Schizophrenia, Attention-deficit hyperactivity disorder (ADHD) 
right across to diseases of muscles (e.g.; myopathy, spinal muscular atrophy), skin (e.g.; 
Hermansky-Pudlak syndrome), and systems (e.g.; severe combined immunodeficiency) are 
also linked to this chromosome; (figure 2.4). An interesting fact is that schizophrenia and 
ADHD are found to have susceptible loci on this chromosome and are co-morbid disorders 
with autism as all the symptoms fall under the spectrum of ASD. 
 
The sequencing of this chromosome in 2001 relayed clarity about the gene/s existing on the 
chromosome (Fig 2.3). Chromosome 5 is known for the gene/s families it harbors some 
include Interleukin gene family and Protocadherins. The 'interleukins' are a family of 
polypeptides belonging to the family of 'cytokines', i.e. cell communications (Malkovský et 
al., 1988). Protocadherins, belong to the super family of cadherins. These glycoproteins play 
a significant role in the formation of neuronal connections in the human adult brain 
(Takeichi, 1995, Gumbiner, 1996, Shapiro and Colman, 1999, Treffert, 1999, Tepass, 1999, 
Wu and Maniatis, 2000). 
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Figure 2.3: Chromosome 5 and gene- and trait associated diseases (The Gene Gateway 
Workbook, 2011) 
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Figure 2.4: The fully sequenced human chromosome 5 summary, (Ensemble, 2011)  
 
2.1.5 Protein dysfunction of CDH10 and relevance to autism 
In the case of a mutated gene, the end results sometimes in a mutated protein which in turn 
causes a problem as the protein cannot perform its original functions. Mutations of genes 
have been known to be the causative agent for various medical conditions. An example of 
Length (bps): 180,915,260 
Known Protein-coding Genes: 845 
Novel Protein-coding Genes: 27 
Pseudogene Genes: 650 
miRNA Genes: 83 
rRNA Genes: 25 
snRNA Genes: 106 
snoRNA Genes: 61 
Misc RNA Genes: 68 
SNPs: 1,991,185 
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one such mutation would be that of the aryl hydrocarbon-interacting protein (AIP) gene. It 
has been shown that the mutation of this gene in pituitary adenomas to be a causative agent 
for acromegaly also known as ‘gigantism’  disease (Chahal et al., 2011).  
 
The CDH10 gene encodes for a cell adhesion molecule previously stated in section 2.1.1 
above.  The protein expressed by this gene is required to interact with β-catenins, which 
means that in the case of an ineffective protein expressed, connection between membranes 
could be ineffective as well. Looking at the structure of the gene, the EC domain and CP 
domain and their functions, it is easy to deduce that loss of function or decreased function 
will cause overall disruption by inhibiting binding which would result in the 
underdevelopment of the CNS.  CDH10 along with CDH9 and other cadherins have been 
investigated as these genes codes for “cell-adhesion molecules which has potential roles in 
the pathogenesis of ASDs” (Wang et al., 2009). With a loss of function these molecules 
cannot assist in the development at the embryonic stage which results in typical symptoms 
displayed in ASDs. The study also concluded that CDH10 gene showed more strong 
significant SNP association as compared to other genes like neurexin and contactin (Wang et 
al., 2009). 
 
2.1.6 CDH10 SNP selection 
According to the NCBI website, approximately 3298 SNPs exist for the CDH10 gene. 
Disorders that have been associated with the gene would include pancreatic cancer, prostate 
cancer and ASD (The National Centre for Biotechnology Information, 2013). A study on 
neurodevelopment showed that CDH10 and CDH9 (with SNPs rs4307059) were associated 
with suicide (Chojnicka et al., 2012).  
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A genome wide association study in 2009 focused on selected genes implicated in ASD. 
According to Wang et al., (2009), the 5p14.1 locus of the fifth chromosome held strong 
genetic variants associated with ASD. This study was conducted on two cohorts; one of 780 
families with children, second cohort of 1204 autistic individuals and 6491 non-autistic 
individuals with European ancestry. The study found six SNP variants between genes CDH10 
and CDH9 yielded strong signaling for ASD pathogenesis of the SNPs rs4307059, had the 
most significant signal (P= 3.4X10
-8
). Amongst these there were five other SNPs with p 
values ranging between 1.7 X10
-5
 to 6.2X10
-7 
in the discovery cohorts (Wang et al., 2009). 
 
SNPs (rs4307059 and rs4327572) were selected for this study for this reason. Rs4307059 and 
rs4327572 are two inter-genic SNPs found at positions 26003460 and 26008578 respectively 
on chromosome five (Wang et al., 2009). The SNP rs4307059 has an orientation plus N with 
minor to major allele of C/T. Rs4327572 has an orientation plus N with minor to major allele 
of T/C. 
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2.2 Hypothesis  
It is hypothesized that there is an association between the prevalence of SNPs (rs4307059 and 
rs4327572) of the CDH10 gene with autism status in the SA population. 
2.2.1 Aims 
 The intention for this study was to determine if there is an association between SNPs 
(rs4307059 and rs4327572) of CDH10 gene and the status of autism in the SA 
population.  
2.2.2 Objectives 
 To genotype the SNPs rs4307059 and rs4327572 of the CDH10 gene in the healthy 
and autistic SA population  
 To determine the association of allele  and genotype distribution  for the SNPs 
rs4307059 and rs4327572 
 To determine the association of SNPs rs4307059 and rs4327572 with autism in SA 
population.  
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2.3 Materials and methods 
Materials 
15ml Greiner tubes  Greiner Bio-One GmbH,   
Frickenhausen Germany 
384-well micro plates       Applied Biosystems,  
California USA 
96-deep-well micro plates       Applied Biosystems,  
California USA 
Applied Biosystems 7900HT Real time PCR    Applied Biosystems,  
California USA 
BuccalAmp™ Extraction Kit      Epicentre®  
Biotechnologies,  
Wisconsin USA 
Microfuge eppMotion 5070      Applied Biosystems,  
California USA 
Nanodrop® ND-1000 Spectrophotometer  Nanodrop® Technologies 
ThermoScientific, 
Massachusetts USA 
Perkin Elmer 7900 PCR system     Applied Biosystems 
         California, USA 
Swabs         Pur wraps MDCL Ltd.  
VWR International,  
Pennsylvania, USA 
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Quickextract
TM
 DNA Extraction solution    Epicentre®  
Biotechnologies,  
Wisconsin USA 
Taqman® SNP Custom Genotyping Assay    Applied Biosystems,  
         California, USA 
TaqMan® Universal Genotype Master Mix    Applied Biosystems, 
         California, USA 
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Methods 
2.3.1 Ethical clearance 
The study protocol was approved by Western Cape Ethics Committee (SR: 5/09/32) of 
University of the Western Cape and Western Cape Education Department. Consent was also 
obtained from principals of schools and parents for the collection and genetic analysis of 
DNA samples, in accordance with the Declaration of Helsinki (Appendix I). 
 
2.3.2 Sample selection criteria and collection 
Healthy group: Samples were collected from neuro-typical healthy students (8-18 years of 
age) from local schools between the ages of 8 and 18 years of age. This group comprised of 
SA subjects of 101 white, 114 black and 118 mixed ancestries.  
Autistic group: The diagnosis was  carried out strictly on the basis of criteria outlined by the 
DSM-IV (Association, 1994). The Childhood Autism Rating Scale (CARS) was administered 
for the assessment of cases (Schopler et al., 1986). Selection of subjects in the study was 
based on clinical and psychological evaluation by experienced psychologist and psychiatrist. 
The autistic group comprised of 86 white, 80 black and 68 mixed ancestries unrelated SA 
children. 
Collections: The samples were collected from autistic individuals studying in schools for 
children with special needs in Cape Town and Gauteng Province whereas the controls 
samples were collected from schools in the Western Cape. The collection entailed the 
individual’s cheek being swabbed with a sterile swab. This action, rubbing of the swab 
against the inside of the individual’s cheek for one minute was done in duplicate. The swabs 
were placed in sterile 15 ml Greiner tubes then labeled and stored at -20
o
C. 
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2.3.3 SNP selection and primer design  
Due to a large number of identified SNPs CDH10, using the Applied Biosystems website a 
SNP assay could therefore be generated. The SNPs rs4307059 and rs4327572 for the gene 
CDH10 were identified from literature of a previously conducted experiment in the European 
population by Wang et al., (2009). Using SNP genotyping, Taqman® technology, the 
selected SNPs can be made to order using the NCBI database. 
 The Primers for these SNPs were pre-designed and obtained from the Applied Biosystems 
Website (Applied Biosystems, 2010).  
The TaqMan® Custom genotyping assay were labeled VIC and FAM to the sequences  
Rs4307059: 
5‘-AGCTTTCACTGATGTGTCCGAATTG C-3‘and 
5‘-TTCATGTAACCAGGATATTTTCCAT- 3‘  
Rs4327572: 
5‘-ATTTTATAAATACTTATAAAGCAAA C -3‘ and 
5‘-TAAAACAGCAAAATATGAAAAAGACA -3’ 
 
2.3.4 DNA extraction 
Using BuccalAmp™ Extraction Kit, DNA was extracted from the samples collected with 
swab. This was done by removing the swab tip and transferring it to a 2 ml Eppendorf tube 
and adding a 250 µl of QuickExtract™ DNA solution 1.0 followed by a 1 minute incubation 
period at 65
o
C. Extraction continued with vortexing the tube for 15 seconds, incubated for 4 
minutes at 98
o
C with a further 15 second vortexing and stored at -20
o
C until quantification. 
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2.3.5 DNA quantification 
DNA concentration was determined by using a NanoDrop®ND-1000 Spectrophotometer. 
 
2.3.6 PCR preparation 
Following quantification, the DNA samples were diluted (final concentration 20 ng/µl) into a 
96 deep-well plate with double distilled water. To the first row in the plate, 50 µl of ddH2O 
was aliquoted to function as negative control, (row labeled A). A PCR reaction sample mix 
was then prepared for samples as follows: 
1680 µl of Taqman ®Universal genotyping Master mix were added with 840 µl of double 
distilled water in a tube and vortexed.  
 
84 µl of 20x Taqman® SNP Custom Genotyping Assay and 84 µl of double distilled water 
were added to an Eppendorf tube and vortexed. The tube was covered with foil as the assay is 
light sensitive. Following the vortexing, the samples were mixed and with the use of the 
microfuge eppMotion 5070 automated pipetting system, were then transferred to 384-well 
plates along with the master mix to a final volume of 5 µl. 
 
2.3.7 PCR amplification, parameters and detection  
The PCR reactions were amplified using a Perkin Elmer 7900 PCR with the following 
conditions. An initial holding step was carried out for 2 minutes at 50
o
C followed by 40 
cycles of: Denaturing for 10 minutes at 92
o
C followed by annealing for 15 seconds at 60
o
C 
and extension at 60
o
C for 60 seconds. The resulting amplified products were read on the 
 
 
 
 
53 
   
Applied Biosystems 7900HT Real-Time PCR System and recorded. Although 333 controls 
and 234 autistic samples were genotyped, not all rendered a signal. 
 
2.3.8 Statistical analysis 
These frequencies were subjected to Chi Square testing for the C and T alleles in the SA 
healthy and the SA autistic groups. Probabilities for associations were done using 
computational methods (Graphpad.com, 2011) where a P <0.05 are significant.  
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2.4 Results  
For SNPS rs4307059, the present study group was comprised of typed case (188, unrelated 
autistic children) and typed controls (212, unrelated healthy children) where the respective 
figures for rs4327572 were 72 and 209 respectively.  For statistical correction, some of the 
subjects were excluded from the actual number of collected subjects.  
 
2.4.1 SNPs rs4307059 and rs4327572 of CDH10 gene 
The following results were obtained from the Taqman® SNPS custom Genotyping Assays. 
2.4.1.1 rs4307059 Allele and genotype data 
The allele and genotype data were collected for the SNP rs4307059 on the CDH10 gene. The 
data were obtained for both the healthy and the autistic SA population and the clusters 
represented in the figure 2.5 (a and b) indicates the distribution for the genotypes in the 
healthy and autistic SA population. In the SA healthy population the percentage distribution 
of the TT, CT, and CC genotypes were 71.2%, 20.8% and 8% respectively whereas the 
autistic population had distribution percentages of 65.4%, 28.7% and 5.9% respectively (table 
2.2). Statistically, no significant differences were observed between the healthy and the 
autistic. The T allele and C allele frequency were 81.6% and 18.4% for the healthy group 
while the respective values among autistic subjects were 79.8% and 20.2% (table 2.2).  
 
 
 
 
    
(a)                (b)     
Figure 2.5: Allelic discrimination plot for the Taqman SNP rs4307059 Custom Genotyping assay for the (a) healthy and (b) autistic S A 
population. The blue, green and red cluster represents the homozygous and heterozygous genotypes which is TT, CT and CC respectively 
for this SNP in the healthy and autistic populations.  The clusters thus represent the distribution for these genotypes in the population 
groups in this study. 
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Table 2.2: Genotype counts and allele frequencies in three ethnic groups, stratified by autism studies in SA population in normal individuals for rs4307059,  
(significant *P<0.05)
Ethnic group Number Genotype P-Value 
 
Allele (%) P-Value 
  TT (%) CT (%) CC (%)  T    allele C allele  
Total South African     
Healthy 212 151(71.2) 44(20.8) 17(8.0) 
0.3054 
346(81.6) 78(18.4) 
0.8094 
Autistic 188 123(65.4) 54(28.7) 11(5.9) 300(79.8) 76(20.2) 
     
SA White     
Healthy 55(26) 19(34.5) 25(45.5) 11(20) 
0.1165 
346(81.6) 78(18.4) 
0.1340 
Autistic 69(37) 34(49.3) 28(40.6) 7(10.1) 300(79.8) 76(20.2) 
      
SA Black   
Healthy 85(40) 79(92.9) 6(7.1) 0 
0.5472 
164(96.5) 6(3.5) 
0.5638 Autistic 74(39) 65(87.8) 9(12.2) 0 139(93.9) 9(6.1) 
     
SA Mixed   
Healthy  72(34) 53(73.6) 13(18.1) 6(8.3) 
0.0513 
119(82.6) 25(17.4) 
0.1672 
Autistic 45(24) 24(53.3) 17(37.8) 4(8.9) 65(72.2) 25(27.8) 
5
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Figures 2.6 and 2.7 illustrate genotype frequency percentage and the allele frequency 
percentage of autistic and healthy SA population. In the healthy SA white population the 
percentage distribution of the TT, CT, and CC genotypes were 34.5%, 45.5% and 20% 
respectively whereas the autistic population had distribution percentages of 49.3%, 40.6% 
and 10.1%  respectively. Statistically, there were no significant differences observed between 
the healthy and the autistic genotypes for this group. The allele frequency for the T allele was 
higher with 81.6% and 18.4% for the C allele in the healthy group whereas the autistic had a 
slight decrease of the T allele having a 79.8% frequency and the C allele having an increase 
to 20.2%. There was no statistical significant association of distribution for the healthy and 
autistic genotyping in the SA population.   
 
In the SA black healthy population, the percentage distribution observed for the TT, CT, and 
CC genotypes were 92.9%, 7.1% and 0%, respectively compared to the autistic population 
with distribution percentages of 87.8%, 12.2% and 0%. It was interesting to note that the 
black group does not have any CC genotype.  In terms of statistical significance, no distinct 
significant differences were observed between the healthy and the autistic individuals. The 
frequency of the T allele was observed to be highest (96.5%) while the C allele had the 
lowest frequency (3.5%) as compared to other ethnic groups for the healthy group.  The 
autistic of had a slight reduction in T allele frequency (93.9 %) and the C allele increased to a 
6.1% frequency as compared to the expected frequencies in the healthy group. P-values 
among healthy and autistic individuals for allelic genotypic frequencies were 0.5638 and 
0.5472, respectively. There was no statistical significant difference with respect to the allele 
and genotype frequencies for this ethnic group. 
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In the SA mixed race healthy population, the percentage distribution of the TT, CT, and CC 
genotypes were 73.6%, 18.1% and 8.3 % respectively, whereas the autistic population had 
distribution percentages of 53.3%, 37.8% and 8.9%. The T allele frequency had the same 
pattern with the higher percentages of 82.6 % and 17.4% C allele frequency in the healthy 
group. The autistic had a slight reduction with the T allele having a 72.2 % and the C allele, 
27.8% frequency. The observed P value shows that there was no statistical significant 
difference among healthy and autistic subjects with respect to their genotype and allelic 
frequencies. 
 
 
 
 
 
   
(a)   (b)      
Figure 2.6: Percentage of genotype TT, CT and CC for the SNP rs4307059 of the CDH10 in (a) healthy and (b) autistic SA population 
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(a)         (b)    
Figure 2.7: Percentage of the alleles C and T for the SNP rs4307059 of the CDH10 gene in (a) healthy and (b) autistic SA population 
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2.4.1.2. rs4327572 Allele and genotype data 
The allele and genotype data were collected for the SNP rs4327572 on the CDH10 gene. The 
data was obtained similarly for both the SA healthy and the autistic population and the 
clusters represent the distribution of the genotypes in the healthy and autistic population 
(figure. 2.8). 
 
In the SA healthy population, the percentage distribution of the TT, CT, and CC genotypes 
were 1.9%, 26.8% and 71.3% respectively, in comparison with the autistic population with 
distribution percentages of 4.2%, 27.8% and 68.1% (table 2.3). The frequency of the T allele 
was higher in autistic (18.1%) compared to the healthy (15.3%) while the allele frequency for 
the C allele was higher with 84.7% in healthy group and 81.9% in the autistic group. The 
allele and genotype frequency of this SNP indicated no significant association of either the 
allele or genotype frequency to autism with probabilities of P= 0.7409 and P=0.5516. 
 
In the SA white healthy population, the percentage distribution of the TT, CT, and CC 
genotypes was 1.7%, 35.6% and 62.7% respectively when compared to the white autistic 
group with a distribution percentage of 6.3%, 31.3% and 62.5% for those genotypes 
respectively. The T and C alleles had a frequency of 19.5% and 80.5% for the healthy group 
in comparison to the autistic with 21.9% and the C allele, 78.1 % frequency. No statistical 
significant association was observed for this SNP with autism in the white SA group.  
 
 
 
 
 
   
 (a)      (b)         
Figure 2.8: Allelic discrimination plot for the Taqman SNP rs4327572 Custom Genotyping assay for the (a) healthy and (b) autistic SA 
population 
6
2
 
 
 
 
 
   
Table 2.3: Genotype counts and allele frequencies in the three different ethnic groups, stratified by autism studies in SA population and in 
compassionate normal individuals for rs4327572, (significant *P<0.05) 
Ethnic group Number Genotype P-Value  Allele (%) P-Value 
  TT (%) CT (%) CC (%)  T    allele C allele  
Total South African     
Healthy 209  4(1.9) 56(26.8) 149(71.3) 0.5516 65(15.3) 354(84.7) 0.7409 
Autistic 72 3(4.2) 20(27.8) 198(68.1) 26(18.1) 472(81.9) 
     
SA White     
Healthy 59(28) 1(1.7) 21(35.6) 37(62.7) 0.4914 23(19.5) 95(80.5) 0.9298 
Autistic 32(44) 2(6.3) 10(31.3) 20(62.5) 14(21.9) 50(78.1) 
      
SA Black   
Healthy 67(32) 2(3) 13(19.4) 52(77.6) 0.7216 17(12.7) 117(87.3) 0.7718 
Autistic 18(25) 0 3(16.7) 15(83.3) 3(8.3) 33(91.7) 
      
SA Mixed   
Healthy  83(40) 1(1.2) 22(26.5) 60(72.3) 0.5012 24(14.5) 142(85.5) 0.6237 
Autistic 22(31) 1(4.5) 7(31.8) 14(63.6) 9(20.5) 35(79.5) 
6
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The percentage distribution of the TT, CT, and CC genotypes in the SA black healthy 
population were 3%, 19.4% and 77.6% whereas the autistic population observed distribution 
percentages of 0%, 16.7% and 83.3%. The T and C allele frequency witnessed a 12.7% and 
87.3% frequency for the healthy group. Two interesting observations were that there were no 
TT genotypes in the black autistic group and that the % C allele is the highest in this group, 
i.e. 87.3% in the healthy and 91.7% in the autistic group. No significant association of 
genotype and allele frequencies with autism in the SA black population (P= 0.7216 and 
P=0.7718).   
 
The SA mixed-raced healthy population had the percentage distribution of the TT, CT, and 
CC genotypes of 1.2%, 26.5% and 72.3 % respectively whereas the autistic population had 
4.5%, 31.8% and 63.6% respectively. The allele frequency for the T allele observed 14.5% 
and the C allele an 85.5 % frequency for the healthy group. When one compares the % T and 
C allele between the SA mixed autistic group with SA black autistic group, the T allele is 
higher i.e. 20.5% compared to 14.5%. In the Case of the C allele, % C allele is higher in the 
SA black autistic compared to the SA mixed autistic group namely, 97.5% compared to 
79.5%. No significant association of allele and genotypic frequencies with autism using chi 
square calculation (P=0.6237 and P=0.5012). 
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 (a)            (b)  
Figure 2.9: Percentage of genotype frequency CC, CT and TT for the SNP rs4327572 of the CDH10 in (a) healthy and (b) autistic SA population 
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 (a)   (b)     
Figure 2.10: Percentage of allele frequency of C and T for the SNP rs4327572 of the CDH10 gene in (a) healthy and (b) autistic SA population 
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2.5 Discussion   
The present study was aimed at identifying the genotyping frequencies and allelic distribution 
of the SNPs rs4307059 and rs4327572 of CDH10 gene in the different ethnic groups for both 
healthy and autistic population groups. Furthermore it also aimed to identify the association 
of these genotypes and alleles with autism.  
 
2.5.1 SNP analysis rs4307059 
The present study represents the first report on genetic association studies on the CDH10 
gene with the two SNPs rs4307059 and rs4327572 in a SA population. The distribution for 
the SNP rs4307059 has been observed globally for statistical purposes but not in association 
studies with disorders. To date, only two studies have found association between the SNP 
rs4307059 and the etiology of autism (Wang et al., 2009, Prandini et al., 2012). Figure 2.11 
gives a representation of the T and C allele distribution of rs4307059 globally. 
 
Figure 2.11: Global distribution and prevalence of the SNP rs4307059 (Applied Biosystems, 
2012) 
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In the present study, the T allele is more prevalent in all ethnic groups, be it healthy or 
autistic. The healthy black group has the highest prevalence of the T allele at 96.5% with an 
only 3.5% C allele. The genotypes TT, CT and CC observed similar frequencies over all 
between the SA total groups in terms of ratios, with the TT genotypes more prevalent , CC 
least frequent and the CT with intermediate results in the healthy than the autistic as seen in 
table 2.2. A similar pattern of genotype ratios was observed within the different ethnic groups 
with comparable frequencies ratios between the healthy and autistic.  
  
The CDH10 gene has been investigated in neuroscience since it has such a major function 
with brain development especially in the fetal brain (Abrahams and Geschwind, 2008; Wang 
et al., 2009). Expression of the gene has been observed with in-situ hybridization showing 
that it is localized in the brain of fetus mainly in the frontal cortex region previously 
associated with ASD similarly like the CNTNAP2 which are “well-established to be involved 
with ASD” (Abrahams and Geschwind, 2008, Wang et al., 2009). Two independent studies, 
reported a significant association for the T allele and the etiology for autism with a strong 
probability of P=3.4X10
-8 
and P= 0.017 in two different populations (Wang et al., 2009, 
Prandini et al., 2012). The degree of freedom for their study was established at 2 where the p-
values are determined at 0.05% significance or cut off at 5.991. The ancestral allele T was 
found to be the risk variant in the European study with 0.65 frequency whereas the frequency 
of this allele for all African populations is 1.00 (Mcclellan and King, 2010). The results for 
their study indicated that the population was in Hardy Weinberg equilibrium. When 
compared to the European study, it was observed for this SNP rs4307059 to be significant 
with a P=3.4X10
-8
, very strong signal association for common variants with susceptibility to 
ASD (Wang et al., 2009). In an Italian study, done on families present of ASD, the T allele 
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demonstrated a strong signal for association with a probability of P=0.017 (Prandini et al., 
2012). 
 
2.5.2 SNP analysis rs4327572 
The SNP rs4327572 along with rs4307059 have been reported by Wang et al., (2009) to have 
been significant in terms of the frequencies of the genotypes for the ancestral and minor 
alleles, T and C. The genotypes TT, CT and CC observed a similar trend with regards to the 
frequencies over all between the SA total groups as seen in table 2.3. The TT genotype 
observed as the least throughout the different populations in the healthy although the autistic 
observed higher incidence than compared to the healthy. Throughout this study, the T allele 
showed slightly higher prevalence in the autistic as compared to the respective healthy groups 
with the exception of the black autistic observing 8.3% T allele occurrence but 12.7% in the 
healthy. TT genotype was observed in in  3% of healthy black population but it was 
completely absent in autistic population.. This result could have been affected by the number 
of typed samples  TT genotype might have different frequencies in a bigger sample size. 
Likewise the CC genotype had the opposite pattern at being observed at a slightly higher 
prevalence in the healthy groups with the exception of the black when compared to the 
autistic. Similarly the C allele had prevalence to some extent higher in the healthy groups 
with exception of the black group observing a spike of 91.7% in the autistic to of 87.3% in 
the healthy. The CT genotype had observed small difference between the SA healthy (26.8%) 
and autistic (27.8%) groups including the different ethnic groups (table 2.3). These results 
thus indicate that the T allele, the minor allele shows more prominence in these population 
groups and is thus associated with the susceptibility to ASD. When compared to the 
European study done by Wang et al., (2009) from which this currents study was inspired.  It 
illustrated a strong signal with a P-value of P= 6.2X10
-7
(Wang et al., 2009). The total group 
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size used for these groups should have rendered statistical significant results either positive or 
not for the allele, however, in this instance only 69.20% of the healthy group and 29.15% of 
the autistic group was successfully genotyped.  
 
The results observed for these SNPs were conducted strictly in a SA population, and even 
though the numbers were low, these results observed could appear to be affected by the 
genetics that confer to the population diversity. The greater part of studies reveals that black 
populations harbour more genetic diversity than non-Black populations for mitochondrial 
DNA sequences, Y chromosome SNPs, Autosomal MicroSatelites as well as Autosomal 
SNPs, to name a few (Excoffier, 2002). These populations have greater levels of genetic 
diversity, extensive population substructure, and less linkage disequilibrium (LD) among loci 
than non-African populations and possess a number of genetic adaptations resulting from 
diverse climates, diets, and the exposure to infectious diseases (Campbell and Tishkoff, 
2008). Other factors that may be used to account for this massive diversity could also include, 
“older onset of population demographic expansion in Africa, population size fluxes and 
periodic extinctions of populations outside Africa” (Excoffier, 2002). However all these are 
“plausible and are not mutually exclusive” to the black population diversity (Excoffier, 
2002). 
 
Lack of significance could also be accounted for by the fact that the SNPs location, that being 
in the intronic region of the CDH10 gene may be selective active in certain populations. In 
general, intronic regions are described as “junk DNA” that disrupts earlier sustained genes 
(De Souza et al., 1997). Proximity to the gene in question can lead to interference as De 
Souza et al.,(1997) discussed the exon theory of genes predicted proteins to be the results 
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from simple compact elements, and that the elements corresponding to exons that introns 
defines the boundaries of such elements  (De Souza et al.,1997).  
 
2.6 Conclusions 
The objectives were to genotype these SNPS’s, to determine the allele and genotype 
frequencies and association with autism. To a degree, these were met, the results for this 
study indicated that the SNP rs4307059 and rs4327572 were successfully genotyped but not 
significant by association in the susceptibility for ASD. The probability for the T allele for 
rs4307059 were P=0.8094 and the C allele for rs4327572 were P= 0.7409 in the SA healthy 
and autistic population. When compared to the other population study for the SNP 
rs4307059, the associations were not made clear for ASD to the SA population. This study 
thus indicates that the CDH10 gene does not indicate relevance to the etiology for ASD in the 
SA population. In conclusion, the hypothesis that an association between the prevalence of 
these SNPs (rs4307059 and rs4327572) of the CDH10 gene and autism status in the SA 
population existed was not found. 
 
2.6.1 Limitation and shortcoming of the present study 
Both Wang et al., (2009) and Prandini et al., (2012) have used massive cohort sizes. In the 
first paper Wang et al., (2009) genotyped 1,204 autistic and 6,491 control subjects with 
strong association signals for these SNPs and 824 subjects in an Italian study by Prandini et 
al., (2012). These studies could positively identify association statistically due to the positive 
hits estimated, benefits of having such a huge group. The present study had numbers far less 
and could account for the estimation of associations and prevalence observed in the SA 
population for both SNPs. The SNP rs4327572 did not have a strong association in the SA 
population and could be as a result to the fact that few numbers were positively genotyped for 
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the SNP. Both of these SNPs were obtained from the same company and used to genotype the 
same population group but yielded different positive hits. This could be relayed to the 
functionality of the SNP since prior to the genotyping, tests were done to assess the degree of 
functionality of each SNP. 
 
2.6.2. Future studies  
The SNPs rs4307059 and rs43275727 were selected from a study done in another population 
based on the strong signal for the association observed. The results obtained were to an extent 
similar, in future; a larger sample size could yield different results or yield more significant 
results. The SA population ethnic groups, if distinctly identified with respect to the mixed 
groups, the ancestry for those groups could shed light and the diversity that goes with it but 
also may add to the etiology of ASD in the SA populations. 
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Chapter 3 
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Abstract 
The SA population is a diverse nation, with the African community comprising of up to 70% 
of the total population and have an interesting genetic history. The proteomics study aimed at 
isolating urinary proteins from African South-African male subjects was conducted. This 
included the purification of the urine protein samples as well as additional steps to remove 
high abundance proteins. The purified protein samples were subjected to 1D and 2D SDS-
PAGE electrophoresis and protein identifications using Electrospray ionization (ESI) mass 
spectrometry. The proteomics study results revealed differential expression of proteins 
between healthy and autistic South Africans. While none of the proteins had direct 
association to Autism Spectrum Disorder (ASD), most had functions related to other diseases 
of which only few could be co-morbid disorders to ASD. This study also shows that more 
investigation with a larger scale of the study could reveal more distinct results for the selected 
group but also for different ethnic groups observed in the SA population. The results revealed 
7 positively identified protein spots with a range of molecular weights and pI’s. The proteins 
identified are Uromodulin, Vitelline membrane outer layer protein homologue, kinninogen-1, 
Alpha-1-Antitrypsin, Ig Kappa chain region C, and CD59 glycoprotein. 
 
 
 
 
 
 
 
 
 
 
 
 
75 
  
 
 
 
Proteomics of autism in a SA 
sample group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
  
Table of Contents 
3. Urinary proteomics in the discovery of biomarkers for autism ................... 78 
 3.1 Proteomic studies on urine ..................................................................................... 78 
3.1.1  Proteomic studies and autism ...............................................................  81 
 3.2 Hypothesis.............................................................................................................  82 
  3.2.1 Aims .......................................................................................................  82 
  3.2.2. Objectives .............................................................................................. 82 
 3.3 Materials and methods ..........................................................................................  83 
  3.3.1 Ethical clearance ..................................................................................... 87 
3.3.2 Study design and population ................................................................... 87 
3.3.3 Sample collection .................................................................................... 88 
3.3.4 Sample preparation ................................................................................. 88 
3.3.5 Depletion of high abundance albumin proteins ...................................... 89 
3.3.6 Protein quantification .............................................................................. 89 
3.3.7 One dimensional (1D) SDS-PGE electrophoresis analysis .................... 90 
3.3.8 Visualization and imaging ...................................................................... 90 
3.3.9 Two dimensional (2D) SDS-PAGE electrophoresis analysis ................. 91 
3.3.10 PDQuest analysis .................................................................................. 93 
3.3.11 Protein excising and identification........................................................ 94 
3.3.11.1 In-gel digestion ...................................................................... 94 
3.3.11.2 Identification using Agilent LLC-ESI QTOF MS ................. 95 
      3.4 Results ................................................................................................................... 96 
3.4.1 1D SDS-PAGE analysis .......................................................................... 97 
3.4.2 2D SDS-PAGE analysis ........................................................................ 100 
3.4.3 Protein profile comparisons .................................................................. 106 
 
 
 
 
77 
  
3.4.4. Protein identification by MS/MS mass spectrometry analysis ............ 110 
3.5. Discussion ........................................................................................................... 113 
3.5.1 Uromodulin/Tamm Horsfall protein (THP)  
(UROM Human: P07911)  .................................................................... 117 
3.5.2 Vitelline membrane outer layer protein 1 homologue  
(VMO1 Human: Q7Z5L0)  ................................................................... 118 
3.5.3 Kininogen-1 (KNG1 Human: P01042)  ................................................ 119 
3.5.4 Alpha-1 antitrypsin (A1AT Human: P01009)  ..................................... 120 
3.5.5 Ig Kappa chain C region (IGKC Human: P01834)  .............................. 121 
3.5.6 CD59 glycoprotein (CD59 Human: P13987)  ...................................... 121 
3.6 Conclusion ........................................................................................................... 123 
3.6.1 Limitation on study ............................................................................... 123 
3.6.2 Future studies ........................................................................................ 124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
  
3 Urinary proteomics in the discovery of biomarkers for autism 
3.1 Proteomic studies on urine 
It has been demonstrated that proteomic studies can be done using urine as source due its 
properties (Wu et al., 2010a). The term “proteomics” and its technologies have been 
explained in the previous section (Chapter 1). Biomarkers are biological indicators that are 
“used as an index of the intensity of a disease or other physiological state in the organism” 
(Majkić-Singh, 2011).  
 
The completion of the Human Genome project has shifted the focus towards  the 
understanding of function and structure of the human genome through the identification of 
protein structure, protein-protein interaction and their differential expression (Bae et al., 
2003). In the post genomic era, proteomics has been considered increasingly important 
(Pandey and Mann, 2000). It plays a significant role in clinical useful applications through 
the study of changes in protein expression levels or post translational modifications (Vidal et 
al., 2005). 
 
Proteomics is a promising approach for the detection and identification of novel biomarkers 
using various biological fluids such as urine, plasma serum and saliva. Out of those, urine is 
considered to be the most attractive proteomic sample due to several advantages. Urine is a 
filtrate of blood and therefore contains a similar protein composition to that of blood. This 
makes it more useful for experimentation of protein profiles and it may hold information 
about the changes that may take place within the body (Barratt and Topham, 2007). These 
protein changes highlight the role of peptides as potential biomarkers. It is noninvasive and 
easily obtained. Urinary proteins and peptides are reported to be stable and can undergo 
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insignificant proteolysis within several hours after the collections (Theodorescu and Mischak, 
2007). Thus it allows for collection of samples without inflicting bodily harm to the subject, 
in large quantities and or repeatedly. The stability of these proteins favors urine as use as an 
interesting source for biomarkers as it can be stored for several years without significant 
alteration to the proteome (Roelofsen et al., 2007, Wu et al., 2010a). Many studies on urinary 
proteins have been reported since 1970’s. 
 
 The urine proteome however differs from one individual to another and is composed of 
extracellular proteins, plasma membrane proteins and lysosomal proteins (Adachi et al., 
2006). Many proteins have been identified using different proteomic techniques such as 1D 
and 2D gel electrophoresis, mass spectrometry (MS), Liquid chromatography-MS/MS and 
many others. Pieper (2004), Pitsikun (2004), Castagna (2005), Sun (2005), and Wang (2006) 
and their collaborators have identified 150, 295, 383, 226, 225 unique proteins (gene 
products) respectively. Furthermore, nearly 1000 protein spots have not been identified when 
resolved on 2D gel (Adachi et al., 2006). 
 
Through the advances in proteomic technology and mass spectrometry, protein discovery in 
urine have increased in its identifications surpassing the numbers previously reported. Using 
high accuracy mass spectrometry, Kentsis et al.,(2009) identified up to 2362 proteins with 
more than 1000 not previously reported in other studies. The proteins annotated were found 
to be associated with 27 common and more than 500 rare human diseases (Kentsis et al., 
2009). Another interesting factor observed in their study was that most of these identified, 
proteins appeared to correspond to expression from the urogenital tract and most likely 
formed in the kidneys or bladder (Kentsis et al., 2009). Furthermore of  those identified, 336 
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proteins were found to be filtered through the glomerular filter suggesting that those proteins 
were from a different organ or area of origin other than that of the kidney organ. This finding 
proposes the use for urine proteomics for studies of human organ and disease etiology 
(Kentsis et al., 2009). The possibility of identifying proteins from other organs could produce 
interesting and significant data in the study of autism without the risk of harm or discomfort 
to sufferers. A study conducted in 2012 reports on anti-neuronal antibodies extracted from 
venous blood. This study aimed at measuring these antibodies as signs for autoimmunity in 
the brain and the relationship to the severity of autism as classed using the Childhood Autism 
Rating Scale. The presences of these proteins were investigated and were found to be 
significantly correlated to the severity of autism in the study group (Mostafa and Al-Ayadhi, 
2012). 
  
There are two ways for characterizing urine, a gel-based and gel-free method because urine is 
easily accessible by noninvasive methods and contains bodily peptides, proteins and amino 
acids related to renal systems (Dihazi and Müller, 2007). By using the gel-based method (1D 
SDS PAGE), Adachi et al.,(2006) showed that the urine proteome contains more than 1500 
proteins including a large proportion of membrane proteins. These proteins were digested 
from the SDS PAGE gels and subjected to HPCL and MS with positive identification. 
 
With a gel based approach in proteomics coupled with MS technology it can and has thus 
been used to identify biomarkers or biological indicators from this source. These techniques 
offer the ability to examine the expression of up to 10,000 protein spots which can be studied 
(Thongboonkerd et al., 2002). Identification of diagnostic biomarkers for autism is very 
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important since early detection and/or rapid diagnostics for this disorder is non-existent 
currently.  The aim of this study was to investigate this possibility.  
 
3.1.1. Proteomic studies and autism 
In recent years proteomics approaches have been used in aid of understanding the etiology for 
autism. Since autism has been previously demonstrated to have associations with  metabolic 
aberrations, immunological functional and gastrointestinal disturbances though the exact 
mechanical significance is unknown (Chugani et al., 1999, Kidd, 2002, Ashwood et al., 2003, 
Yap et al., 2010). Using a non-gel based proteomic approach on blood serum,  Corbett et al., 
(2006) identified differentially expressed apolipoproteins and complement proteins between 
autistic and control subjects. Furthermore Yap et al., (2010) revealed novel findings when 
subjecting autistic urine samples to nuclear magnetic resonance (NMR) spectroscopy. This 
study reported significant metabolic differences in the urine compositions between healthy 
and autistic children. Emond et al., (2013) also reported that there had been a significant 
difference in urinary metabolic profiles between autistic and healthy subjects.  
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3.2.Hypothesis 
It is hypothesized in this study that there are differences in the proteome profile of urine of 
autistic children when compared to healthy children. 
 
3.2.1 Aims 
 To identify the differentially expressed proteins among autistic and healthy subjects. 
 
3.2.2. Objectives 
 To collect urine samples from both healthy and autistic children 
 To extract proteins from urine samples  
 To generate reproducible proteome profiles using 1D and  2D SDS-PAGE 
electrophoresis 
 To identify differentially expressed protein using mass spectrometry 
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3.3.Materials and methods 
Materials 
1.0 mm Spacer glass plates     Bio-Rad, California, USA 
2-Mercaptoethanol      Sigma Aldrich, Missouri, USA 
(3-[(3-Cholamidopropyl)      Sigma Aldrich, Missouri, USA 
dimethylammonio]-1-propanesulfonate) CHAPS  
Short glass plates      Bio-Rad California, USA 
Acetone        Kimix, Cape Town, SA 
Acetonitrile       Kimix, Cape Town, SA 
Acrylamide (30% Bis acrylamide)    Bio-Rad California, USA 
Agarose       Bio-Rad California, USA 
Agilent LC-ESI-QTOF MS Agilent technologies, California, 
USA  
Ammonium bicarbonate      Bio-Rad California, USA 
Ammonium persulphate      Bio-Rad California, USA 
Ampholytes       Bio-Rad California, USA 
Aurum™ Affigel® Blue Mini kit/column   Bio-Rad California, USA 
Bio-Rad Bradford assay dye     Bio-Rad California, USA 
Bovine serum albumin      Sigma Aldrich, Missouri, USA 
Bromophenol blue      Sigma Aldrich, Missouri, USA 
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Coomassie brilliant blue R-250  (CBB R-250)   Bio-Rad California, USA 
DTT (Dithiothreitol)     Fermentas, Thermo scientific,  
Massachusetts, USA 
Ettan™ IPGphorII™ IEF     Amersham Biosciences, GE  
Healthcare UK 
Fermentas unstained Protein ladder    Fermentas, Thermo scientific, 
Massachusetts, USA 
Glacial acetic acid      Merck, Darmstadt, Germany 
Glycerol       Merck, Darmstadt, Germany 
Glycine             Bio-Rad California, USA 
Hydrochloric acid      Merck, Darmstadt, Germany 
Iodoacetamide       Sigma Aldrich, Missouri, USA 
IPG strips       Bio-Rad California, USA 
Lyophilizer Labconco      Labconco, Kansas, USA  
(N,N,N´,N´-tetramethylethylenediamine) TEMED  Sigma Aldrich, Missouri, USA 
PDQuest software basic      Bio-Rad California, USA 
Pharos FX™ Plus Imager,     Bio-Rad California, USA 
(Quantity One imaging Software 4.6.9) 
Phenylmethanesulfonylfluoride (PMSF)    Sigma Aldrich, Missouri, USA 
Plus one dry strip covers fluid     Amersham Biosciences, GE  
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Healthcare, UK 
Propan-2-ol       Merck, Darmstadt, Germany 
Sodium dodecyl sulfate      Bio-Rad California, USA 
Sorvall RC5C centrifuge      Thermo Scientific, Massachusetts,  
USA 
Speed vacuum SC100 Thermo Savant    Thermo Scientific,  
Massachusetts, USA 
Thiourea       Sigma Aldrich, Missouri, USA 
Tris-HCl base       Bio-Rad, California, USA 
Trypsin solution      Promega, Wisconsin, USA  
Urea        Sigma Aldrich, Missouri, USA 
Whatman™ filter paper     GE Healthcare, UK 
 
Buffers and solutions 
 1 X SDS Buffer: 1 part of 10X SDS buffer diluted with 9 parts dH2O 
 1% Sealing agarose gel: 1 g agarose; 0.04% bromophenol blue stock ; dissolved in 
100 ml 1X SDS buffer solution 
 10% Ammonium persulphate: 0.1 g APS dissolved in 1 ml dH2O; prepared fresh 
every two weeks 
 10% Sodium dodecyl sulphate: 10 g SDS dissolved in 100 ml dH2O 
 10X SDS Buffer: 1.92 M glycine (144 g); 0.25M Tris-HCl (30.2 g); 0.1% SDS (10 g);  
dH2O to final volume 1L 
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 12% Separating gel: 30% acrylamide (37.5:1) (4 ml); 10% sodium dodecyl sulphate 
91.25 ml); 3 M Tris-HCl pH 8.8 (1.25 ml); 10% ammonium persulphate (freshly 
prepared) (0.05 ml); 0.02 ml TEMED and 3.43 ml dH2O to final volume of 10ml. 
 2 X SDS reducing buffer pH 6.8:  0.2 M Tris-HCl pH 6.8 (1.21 g); 40% glycerol (20 
ml); 10% SDS (5 g); 0.02% bromophenol blue  (0.01 g); dH2O;   At time of use, 10% 
2-mercaptoethanol (0.15 ml per 1.5 ml aliquot)    
 25mM Ammonium bicarbonate/50% Acetonitrile: 50mM ammonium bicarbonate 
stock plus 1part volume of 100% acetonitrile 
 5% Stacking gel: 30% acrylamide (37.5:1) (0.8 ml); 10% sodium dodecyl sulphate 
0.625 ml); 1M Tris-HCl pH 6.8 (0.625 ml); 10% ammonium persulphate  (0.025 ml); 
20 µl TEMED and 2.905 ml dH2O to final volume of 5 ml 
 50% Acetonitrile: 5 ml acetonitrile; 5 ml milliQ H2O  
 50mM Ammonium bicarbonate: 0.08 g ammonium bicarbonate; 20 ml milliQ H2O 
(Prepared fresh before use) 
 70% Acetonitrile: 1400 μl acetonitrile; 600 μl milliQ water  
 Bio-Rad Bradford protein assay dye: 1 part of protein assay diluted with 4 parts of 
dH2O  
 Bovine serum albumin: 0.005 g of BSA dissolved in 1ml of  urea solubilizing buffer 
 Bromophenol blue stock solution: 1% (100 mg) bromophenol blue, 0.05 M Tris base 
(60 mg), dH2O  to 10 ml 
 Coomassie staining solution I:  10% glacial acetic acid; 0.025% (w/v) CBB R-250; 
25% propanol; double distilled H2O to final volume 1L 
 Coomassie staining solution II: 10% glacial acetic acid; 0.003125%  (w/v) CBB R-
250; 10 % propanol; double distilled H2O to final volume 1L 
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 Coomassie staining solution III: 10% glacial acetic acid; 0.003125%  (w/v) CBB R-
250; double distilled H2O to final volume 1L 
 Destaining solution: 10% glacial acetic acid; 1% glycerol; double distilled H2O to 
final volume 1L 
 Low application buffer : 20 mM Tris-HCl pH 8.3; dH2O 
 Urea solubilizing buffer: 7 M urea, 2 M thiourea, 4% CHAPS dissolved in 100 ml 
distilled H2O  
Methods 
3.3.1 Ethical clearance 
This study has been approved by the UWC ethics committee (SR: 5/09/32) and permission 
was received from the Western Cape Education Department (Appendix I). Furthermore, 
permission was obtained from the school principals to conduct the study at the respective 
schools. Informed consent was obtained from the parents of the respective children 
participating in the study (Appendix I). 
 
3.3.2 Study design and population 
The project was designed as a case-control comparative study involving two groups of 
children diagnosed with autism (experimental group) and without any history of autism 
(control group). The inclusion criteria for the experimental group were to be children/pupil’s 
at school with the diagnosis of autism made by a professional doctor and/or psychologist. The 
study was gender specific to males of African ancestry. Children/pupil’s had to be South 
Africans aged between 6 and 14 years and residing in the Western Cape region. The Informed 
written consent from the parent as well as the school principal and teachers were taken for 
this study. The criteria of selection of the healthy group matched that of the experimental 
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group in terms of the age requirement, gender specificity, and race. Informed consent from 
parents and the school principal were also taken. The healthy group had to display the 
absence of any mental disabilities and any history of mental illnesses for the comparative 
study.  
 
3.3.3 Sample collection 
All samples were collected in Cape Town from the Western Cape region. For the 
experimental group, participants were recruited from Nolunthando School situated in 
Khayelitsha. The healthy group participants were recruited from the Lantana Primary School 
in Mitchell’s plain. A teacher assisted the male subjects during the process of the second 
urination for the day and assured all samples were midstream collections. The urine was 
collected into a sterile 100 ml glass bottles that contained a proteanases inhibitor 
Phenylmethanesulfonylfluoride (PMSF) at a 1 mM concentration to a urine volume of 60 ml. 
All samples were obtained on the school premises. The bottles were kept on ice until they 
reached the laboratory and were stored at -80
o
C. 
 
3.3.4 Sample preparation 
The frozen urine samples were thawed and were clarified by centrifugation at 3,000 x g for 
10 minutes and then filtered through a 0.45 µM syringe filter. Proteins were extracted from 
the urine filtrate utilizing the acetone method (Khan and Packer, 2006).  A urine-to-acetone 
ratio of 1:4 was used and the samples were placed at -20°C for an incubation period of at 
least 12 hours. Subsequent to incubation, the samples were centrifuged for 30 minutes using a 
Sorvall RC5C centrifuge at 16,887 x g and the precipitated pellet was collected. The pellet 
was then subjected to a post precipitation 80% acetone wash and allowed to air dry.  The 
cleaned pellet was suspended in a solubilizing buffer containing 7 M urea, 2 M thiourea and 
 
 
 
 
89 
  
4% 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS)  and placed on 
a vortex overnight at 4
o
C. The resulting solubilized samples were then centrifuged at 20,000 
x g for 10 minutes and the supernatant recovered. A 200-fold dialysis of the recovered 
supernatant was done overnight at 4
oC against 18 Ωcm deionized water. The protein sample 
was recovered and frozen at -80
o
C for 20 minutes followed by freeze drying using a 
Labconco lyophilizer. The samples were collected the following day, labeled and stored in 
lyophilized form at -20
o
C.  
 
3.3.5 Depletion of high abundance albumin proteins  
In this section half of each lyophilized sample for both healthy and autistic groups were 
subjected to an albumin depletion step using the Aurum™ Affi-gel® Blue Mini Kit according 
to the manufacturer’s instruction manual. The beads were drained of residual buffer and 
washed twice with 1 ml of Low Application Buffer. The lyophilized samples were suspended 
in the same Low Application Buffer and transferred onto the Affi-gel® Blue Mini Kit 
columns and allowed to be filtered via gravitational force into sterile 1.5 ml Eppendorf tubes. 
The filtrate collected from the column (albumin free) were re-dialyzed overnight at 4
o
C 
against 18Ωcm deionized water, lyophilized and stored as described in section 3.3.4. 
 
3.3.6  Protein quantification 
All the lyophilized protein samples (healthy and autistic samples both depleted and un-
depleted of albumin) were re-suspended in Solubilizing Buffer. These were quantified using 
the Bradford reagent using bovine serum albumin (BSA) as a standard. Using the Bradford 
(1976) method, a standard curve was generated where BSA was used with the following 
concentrations, 0.5µg/µl, 1µg/µl, 2 µg/µl, 3 µg/µl , 4 µg/µl  and 5 µg/µl. To a cuvette 5 µl of 
 
 
 
 
90 
  
each standard was added to 995 µl of Bradford reagent and incubated for 15 minutes at room 
temperature and the absorbance read on a spectrophotometer at 595 nm. 
For the re-suspended protein samples, two fold dilutions were prepared of which 5µl of each 
of the series were mixed with 995 µl of Bradford reagent. The samples were incubated for 15 
minutes and the absorbance was read at 595 nm using a spectrophotometer. All samples were 
quantified using the Bradford method (Bradford, 1979) and then resolved on a 12% 1D SDS-
PAGE gel. 
 
3.3.7  One dimensional (1D) SDS-PAGE electrophoresis analysis 
With a concentration determined the re-suspended protein samples were subjected to 1D 
analysis. SDS-PAGE gels were prepared with a 12% separating gel and a 5% stacking gel set 
to cast in a 1.0 mm glass plates (Laemmli, 1970). With calculating the final weight of protein 
in the well to 10 µg, 15 µg and 20 µg, samples were diluted with an equal volume of 2X SDS 
reducing buffer, boiled for 5 minutes in a water-bath at 95°C. The samples were subjected to 
a pulse centrifugation prior to loading adjacent to an unstained Fermentas protein ladder. The 
gels were initially electrophoresed at 50 V for 10 minutes followed by 100 V until the 
bromophenol blue dye reached the bottom of the gel. The gels were then stained for 
visualization and imaging. 
 
3.3.8 Visualization and imaging 
The Coomassie Brilliant blue R-250 staining and a destaining solution was used for 
visualizing protein bands and spots. The SDS-PAGE gels were exposed to three steps 
staining and destaining in the following manner: 
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Coomassie Brilliant Blue Stain I: The SDS-PAGE gel was submerged into 250 ml of this 
stain, heated for 30 seconds in a microwave and left at room temperature on a shaker for 30 
minutes. Following this, the Coomassie stain I was decanted. 
 
Coomassie Brilliant Blue stain II: Subsequent to the first stain I step, the SDS-PAGE gel was 
then submerged into 250 ml of this stain, heated for 30 seconds in a microwave, and left at 
room temperature on a shaker for 30 minutes. The second stain was then decanted in 
preparation for the final staining step 3. 
 
Coomassie stain III: Following stain II, the SDS-PAGE gel was submerged in 250 ml of stain 
III, heated for 30 seconds in the microwave, and left at room temperature for 30 minutes on a 
shaker. The stain was then decanted, and the gels were destained in 250 ml of destaining 
solution with shaking at room temperature until distinct protein bands were visualized. 
 
Imaging: The SDS-PAGE-gels were viewed on Pharos FX™ Plus Molecular Imager, 
utilizing Quantity One® 1D analysis software, and followed by analysis using the PDQuest 
software basic 8.0.1 Gel Imager. 
 
3.3.9  Two dimensional (2D) SDS-PAGE electrophoresis analyses 
There are four main steps in 2D analyses; these include in-gel rehydration, iso-electrical 
focusing (first dimension), equilibration and then the second dimension run which is the 
molecular weight separation of proteins (Thongboonkerd et al., 2002). 
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In-gel rehydration: Protein samples of 50 and 100 µg were used for 2D gel optimization. The 
IPG strips can only harbor 1.25 µl of carrier Ampholytes and 150 µg of protein and total 125 
µl of complete mixture. To supplement the balance of total mixture, solubilizing buffer was 
added containing 8% dithiothreitol (DTT).  The samples were subjected to a pulse 
centrifugation and loaded onto a level re-swelling tray. The samples were soaked into a 7 cm 
long IPG strip with pH 4-7 overnight at room temperature covered in Amersham mineral oil. 
 
Iso-electrical Focusing (IEF): Following overnight re-swelling in the tray, the IPG strips were 
rinsed with distilled water and placed on an Ettan™ IPGphorII™ IEF machine with the 
respective ends (positive and negative) aligned and covered with mineral oil. The IEF run 
was set to a three step program, step 1: 250 V for 10 minutes, step 2: 4000 V for 1 hour and 
step 3 4000 V until it reached 12 000 V/hours at 20°C. 
 
Equilibration: This step involved the equilibration of the focused IPG strips in Equilibration 
Buffer I and II. Following IEF, the IPG strips were removed and washed gently by pouring 
distilled water over them and transferred into a tray. Each strip was then incubated in 
Equilibration Buffer I for 10 minutes on a shaker at room temperature after which 
Equilibration Buffer I was decanted and Equilibration Buffer II added following same 
procedure as Equilibration Buffer I (Ngara and Ndimba, 2011). The IPG strips were then 
washed gently using 1 X SDS buffer and prepared for the final step in 2D SDS PAGE. 
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Second Dimension electrophoresis: In the second dimension the IPG strips were subjected to 
separation based on molecular weight. The strips were placed on top of a 12% separating 
SDS-PAGE gel, which were aligned such that the marker was placed at the negative end of 
the strip. A square cut (4 mm X 4 mm) piece of Whatman™ filter paper was soaked in 
Fermentas Unstained Protein ladder and placed adjacent to the strip. To seal off the strip, a 
1% agarose solution was loaded, sealing the strip in place. The strip was then set to run on the 
gel for 100 V until the bromophenol blue dye reached the bottom of the gel. Once completed, 
the SDS-PAGE gels were recovered and stained for visualization and imaging as described in 
section 3.3.7. 
 
3.3.10 PDQuest analysis 
The PDQuest basic 8.0.1 2D analysis software was used to conduct 2D SDS PAGE analysis 
between the two samples sets used in this study. This software was used since it allows one to 
determine differential expression, quantitative differences and statistical significance between 
respective groups. In this analysis four parameters were used to compare the healthy and 
autistic samples. A quantitative parameter was used to determine the fold change in 
expression with and upper limit of 1.5 fold and lower limit of 0.5 fold. A statistical 
parameter, the student’s t-test was used with a 90% significance cut-off. Based on these 
parameters only a few spots were identified in this program and used for further analysis. The 
last two were Boolean parameters which allows for the analysis of spots between the group 
by combining and comparing the groups. Those selected were the union of sets and the other 
the intersection between all the sets.  
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3.3.11 Protein excising and identifications 
3.3.11.1  In-gel digestion 
Spots of interest were selected on the bases of PDQuest software basic (8.0.1) analysis. The 
digestion of the spots was done sequentially in 5 steps: washing, destaining, dehydration, 
desiccation and digestion. 
 
Washing: Spots were manually excised by use of a sterile spot-cutter and transferred to sterile 
micro-centrifuge low binding Eppendorf tubes. To the gel pieces, 200 µl of distilled water 
was added and vortexed slowly for 5 minutes. The water was removed and the step repeated 
thrice. Destaining: To the gel pieces 50% (v/v) 50 mM ammonium bicarbonate and 50% (v/v) 
acetonitrile solvent were added and vortexed for 5 minutes and repeated until the gel plugs 
were colorless to clear. The solution was discarded and clear gel pieces subjected to 
dehydration. Dehydration: To the clear gel pieces 100 µl of 100% (v/v) acetonitrile solvent 
was added and incubated by vortexing slowly for 10 minutes and solution was discarded.  
Desiccation: The gel pieces were dried with the use of a Speed Vacuum SC100. Digestion: 
The washed and dried gel pieces were subjected to tryptic digestion. The peptides were 
digested with 15 µl of 10 ng/ml trypsin solution and incubated at 37
o
C for 12 (minimum) to 
16 hours (maximum). Samples were recovered and the peptides extracted. Extraction: To the 
tryptic protein plugs, 20 µl of 70% acetonitrile was added and incubated on low setting 
vortex for 30 minutes and the supernatant collected. This step was repeated twice and the 
supernatant collected and subjected to desiccation. 
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3.3.11.2  Identifications using Agilent LC-ESI QTOF MS  
Protein spots were digested with trypsin and identified by use of an Agilent 6530 LC-ESI-
QTOF Mass Spectrophotometer.  The identification of selected protein spots were carried out 
by Dr. Zac Macdonald in the Molecular and Cell Biology Laboratory at the University of 
Cape Town. The MS results were viewed using the Agilent Spectra Mill software version 4.0, 
and matched with sequences in the SwissProt database. The process of identification included 
the drying of the digested spots followed by resolubilization in a specific loading buffer and 
injected onto the LC/MS system. For a detailed description of the method and parameters for 
protein identification refer to Appendix II. 
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3.4 Results 
The acetone precipitation and protein extraction method was utilised to obtain urinary 
proteins from both the healthy and autistic South African groups. This included the check for 
protein concentration per gel, additional treatments and purification steps. Purification steps 
had to be implemented to reduce the high ion levels present since urine is a complex mixture 
of solutes, ions and other materials. This was done by dialyzing the samples against 18Ωcm 
distilled water at 4
o
C overnight and followed with lyophilizing to insure a concentrated 
sample. Protein samples were quantified using the Bio-Rad Bradford assay and results for all 
samples ranged between 0.31 and 4.45 µg/µl. Three concentrations were used for gel loading, 
10 µg, 15 µg and 20 µg to establish a standard concentration for the 1D SDS-PAGE profile. 
The 15 µg final protein content gave the best resolution for the 1D SDS-PAGE gel profile. 
Technical triplicates were done for each sample to ensure profiles were consistent (data not 
shown). 
 
The use of an albumin depletion kit was considered to be essential to meet our aims in this 
project. Albumin proteins are known to mask smaller and less abundant proteins and thus 
their removal was incorporated. This meant that part of this experiment was to observe the 
difference in the protein profiles in urine samples with and without albumin. Figures 3.1 and 
3.2 show the urinary protein profiles of six healthy and six autistic subject pre and post 
albumin treatment of samples.  
 
 
 
 
   
3.4.1 1D SDS-PAGE analysis 
A comparison was assessed between the healthy and autistic groups, to establish any differences between the groups, both un-depleted and 
depleted groups.  
                                      
Figure 3.1: Healthy un-depleted and depleted of albumin urine protein 1D SDS-PAGE profiles. Subject’s sample 1 to 6 was loaded in the order 
observed with the un-depleted sample first followed by the depleted sample for each subject. The un-depleted of albumin samples are indicated 
by the a
+ 
and depleted of albumin indicated by a
-
 . This was done for all the samples through 6. M represents the protein marker lane (kDa). Red 
boxes depict the difference between the same sample before and after Albumin depletion. Legend (A) directs to bands which were to indicate the 
presence or absence of albumin. In the pre albumin treatment distinct bands were visible which in the corresponding post albumin treated lane 
were not visible to absent. Legend B directs to bands for subject four, pre and post albumin treatment profiles. In lane a
+
 for subject four shows 
ample protein bands marked in the red box. In lane a
-
 for the same subject post albumin treatment, reveals more bands or enhanced intensities for 
those proteins in that part of the gel. 
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Figure 3.1 depicts the protein profiles  of six normal subjects. This figure shows protein 
profiles pre and post albumin depletion. In the figure, sample (1) was loaded (pre albumin 
depletion) and post albumin depletion. Similarly, in next lanes following samples 2 to 6 were 
loaded in the same order. In the lanes (subject’s 2, 4 and 6) marked by the red square blocks, 
differences were observed in band intensities 
 
Figure 3.2 represents the proteins profiles for the experimental group. All samples were 
loaded for each subject the pre and post albumin treatment for the sample in the same manner 
for the healthy group. The red boxes (legend C) show the results observed from the use of 
albumin removal treatment. The bands appear to be more abundant or present in the depleted 
lanes than the un-depleted lanes of the same sample.  
 
 
 
 
  
 
  
                                      
Figure 3.2: Autistic un-depleted and depleted of albumin urine protein 1D SDS-PAGE gel profiles. As seen subject samples 1 to 6 were loaded 
with the albumin containing and albumin free samples for each subject. The a
+
 here represents the albumin containing sample and the a
-
 
represents the albumin free sample. This was done for all the subjects through 6. M represents the protein marker lane (kDa). Differences 
observed shown in there red boxes (C). 
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3.4.2 2D SDS-PAGE analysis 
Following electrophoresis of samples by 1D SDS-PAGE, the samples were then analyzed on 
2D SDS-PAGE gels to determine their respective quality and protein profiles. The samples 
were resolved on 2D SDS-PAGE gels using 7 cm length of IPG strips of pH4-7. The strips 
were electrophoresed in the second dimension on 12% SDS-PAGE gels at 100 V for 90 
minutes. At first, the un-depleted samples were subjected to 2D focusing, but results showed 
poor resolution and proteins did not migrate on the strip possibly due to the high salt/ion 
concentration. The protein samples for both healthy and autistic groups in both forms, un-
depleted and depleted of albumin were then subjected to the desalting method that included 
the dialysis against 18Ωcm deionized water followed by lyophilization. The figures 3.3, 3.4, 
3.5 and 3.6 show the protein profiles obtained after all the preparations, the albumin removal 
and desalting steps. Technical triplicates were made for each sample to provide consistent 
data. 
 
Figure 3.3 displays the protein profiles for all the healthy South African male samples 
without the removing of the albumin. The profiles positively displayed proteins; in some 
sections of the gels some clusters were observed. Other observations made were the presence 
of large protein spots. This made it difficult to determine whether or not one or more than one 
protein could be present for that size and/or pI.  
 
 
 
 
  
                      
 
 
           
Figure 3.3: Healthy albumin un-depleted urine protein profiles resolved on 12% 2D SDS-PAGE gels pH 4-7. Protein marker 
bands are demarcated on the left in kDa. The arrows in sample 1 indicate protein spots which are observed differently in the post 
albumin step sample (as in figure 3.4). The six samples resolved on 12% PAGE gels, parameters mentioned previously at a 100 
µg final concentration, were arranged in the order in which they were collected.  From left to right in the top row are the samples 
1 to 3 and bottom row samples 4 to 6. This was done similarly for all other proceeding samples. 
A 
50kDa 
30 kDa 
10kDa 
50kDa 
30 kDa 
10kDa 
pH 4            -                     7      pH 4        -                     7          pH 4       -                  7   
1 2 
4 5 6 
3 
1
0
1
 
 
 
 
 
  
 
 
Figure 3.4: Albumin depleted urine protein profiles among healthy subjects resolved on 12% 2D SDS-PAGE gels pH4-7. Protein 
marker bands are noted on the left in kDa. As mentioned all samples were electrophoresed at a 100 µg final protein content onto a 
12% SDS PAGE gel. From left to right in the top row are the samples 1 to 3 and bottom row samples 4 to 6. The arrows for point 
B indicates to protein spots which have observed a difference in resolution when compared to the un-depleted counterpart in 
figure 3.3 for sample 1. 
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Figure 3.4 displays the protein profiles for all the healthy South African male subject samples 
which have undergone the removal of the abundant protein albumin. The six samples were 
electrophoresed under the exact same conditions with regard to gel percentage, protein 
concentrations, electrophoresis parameters and staining regime. The expected outcome for 
these samples was to observe a difference in protein spots with regards to number of spots 
and resolution of smaller spots. The red arrow in figure 3.3 and 3.4 shows a portion of one 
sample that indicates the difference between an albumin removed sample and an un-depleted 
sample. The label A (figure 3.5) shows a few protein spots which were more intensified 
shown by point B (figure 3.6). The dark spot predicted to be albumin which has a molecular 
weight of 67 kDa were expected to appear in the top part of the gels. Between the groups, 
higher molecular weight protein spots were observed in the un-depleted groups in this area of 
the gels, when compared to their counterpart in the albumin depleted groups, some of these 
appear to have either a reduced amount of protein in that area or nothing at all. 
 
Figure 3.5 displays the protein profiles for all the autistic African male samples which have 
undergone the removal of the abundant proteins albumin. The six samples were processed 
with the exact same parameters as the healthy un-depleted and depleted of albumin sample. 
The arrangement of samples was displayed in order of collection as well with samples 1 to 3 
in the top row left to right and 4 to 6 in the bottom. The treated samples for this experimental 
group are shown in figure 3.6. To the naked eye, when observing for differences in profiles, 
some were seen in particular a very distinct presence of more spots after albumin removal 
treatment. In figure 3.6, sample 3 appeared to have more spots (point D) than seen in the un-
depleted sample 3 (point C) in figure 3.5. From these gels and their comparison, it could be 
stated that the albumin removal may have removed the albumin and associated proteins and 
may have enhanced or unmasked the resolution for lower molecular weight proteins. 
 
 
 
 
  
 
 
Figure 3.5: Autistic albumin un-depleted urine protein profiles resolved on 12% 2D SDS-PAGE gels, pH4-7.  Protein marker 
bands are demarcated on the left side in kDa. Seen above label C indicates protein spots which observes different profile in the 
depleted group for sample 3 
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Figure 3.6: Autistic albumin depleted urine protein profiles resolved on 12% 2D SDS-PAGE gels pH4-7.  Protein marker bands 
are demarcated on the left in kDa. The arrows in sample directs to a cluster of protein spots not previously observed for that 
sample pre albumin depletion. 
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3.4.3 Protein profile comparisons 
PDQuest™ basic version 8.0 2D analysis software was used to match spots between sample 
gels as well as measure those abundant with quantity differences, and a statistical test the 
student’s t-test. The PDQuest quantity set parameter was used to compare expression patterns 
with an upper limit of 1.5 fold and lower limit of 0.5 as described in section 3.3.10.  
 
The protein spots were analysed from both the undepleted group and the depleted group 
(healthy and autistic) to establish whether or not the abundant proteins may affect the profiles 
for the different groups. The un-depleted healthy protein profiles were analysed against the 
autistic un-depleted profiles and the healthy depleted profiles against the autistic depleted 
group. The data obtained from the software presented spots for both the undelepleted and 
depleted groups.  From those only a few were either statistically significant, quantitiatively 
significant or in some cases considered both. The following tables provides a list of spots 
identified as significant using this software. The  spots in table 3.1 and tables 3.2 displays the 
spots for the un-depleted and depleted groups nominated from PDQuest.  Figures 3.7a and 
3.7bIn figure 3.7a and 3.17b ,  10 spots were selected for identification. These figures 
indicate the spots from the two individual gels for spots one to five and six to ten.  Spots one 
to five in figure 3.7a were the albumin depleted sample whereas spots in figure 3.7 b indicate 
the sample from prealbumin depletion. 
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Table 3.1: Protein spots selected for identification of albumin depleted samples for the 
healthy and autistic groups. 
The yellow squares represent the presence of a protein spot (some may differ in resolution) 
whereas the yellow circles represent the absence of a spot. Bar graphs: red bars- healthy and 
green bars- autistic. The bar graphs display the expression patterns of healthy and autistic 
samples for the respective protein spots *SSP- Sample spot Protein and the occurrence of the 
protein within the samples. 
Spot number Healthy  Spot review Autistic  
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
 
 
 
5 
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Table 3.2: Protein spots selected for identification of albumin un-depleted samples for the 
healthy and autistic groups. 
The yellow squares represent the presence of a protein spot (some may differ in resolution) 
whereas the yellow circles represent the absence of a spot.  
Spot number Healthy Spot review Autistic  
6  
 
 
 
7 
 
 
 
8 
 
 
 
9 
 
 
 
10 
 
 
 
 
 
 
 
   
 
 
(a)   (b)  
Figure 3.7a: Healthy SA albumin depleted urine protein profile resolved on 12% 2D SDS-PAGE gel with selected spots for analysis.  
Figure 3.7b: Healthy SA un-depleted of albumin urine protein profile resolved on 12% 2D SDS-PAGE gel with the respective spots for analysis.
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3.4.4 Protein Identification by MS/MS mass spectrometry analysis 
The results yielded were a list of potential protein identities in an MS Excel sheet format. 
Positive identification for protein spots subjected to mass spectrometry is based on a scoring 
system of the MOWSE score. This score is calculated as -10Log (P), where P stands the 
absolute probability (P). The score is based on the likelihood that the experimental sequences 
observed matched to database sequences (e.g. Mascot, MOWSE (HGMP), PeptIdent) is a 
random event. The list contains the unique score for each possible protein, the percentage of 
peptide matches between the theoretical and actual proteins as well as the percentage of 
coverage across the protein map compared to a database. The output data were obtained and 
tabulated accordingly in tables 3.3 and 3.4.  Table 3.3 presents the list of spots identified from 
the MS analysis. The table includes the estimated and theoretical pI/MW (kDa) for each spot 
with the confidence score obtained as well as the amount of peptides matched during the 
identification process. The 10 spots were analyzed however 3 spots were identified as 
contaminants instead and were labeled red (figure 3.3).  Table 3.4 presents the list of 
positively identified proteins from the MS analysis.  Based on the PDQuest software, these 
spots were either quantitatively significant or statistically significant based on the student’s t-
test. This table also provides indication list of proteins identified in t two groups  
 
 
 
 
 
 
 
 
                       Table3.3: List of proteins identified by mass spectrometry from healthy and autistic samples 
Spot 
Number 
a
 
Protein Name   Accessi
on 
number 
b 
 
Estimated 
pI/MW(kD
a)
c
 
Theoretical 
pI/MW(kDa) 
d
 
Confidence  
score 
(p<0.05)
e
 
Peptides 
matched/ 
coverage (%) 
       
1 Uromodulin P07911 4.4/85 5.05/69.71 262.69 15/26.5 
2 Vitelline membrane outer 
layer protein homologue 
Q7Z5L0 4.7/18 4.90/21.52 78.1 4/28.7 
3 Kininogen-1 P01042 5/60 6.34/71.91 170.67 10/16.7 
4 Alpha-1-antitrypsin P01009 5.1/60 5.37/46.71 148.97 8/24.1 
5 Ig Kappa chain region C P01834 5.6/40 5.58/11.60 125.84 6/79.2 
6 CD59 glycoprotein P13987 4.5/20 6.02/14.17 67.02 4/25 
 (7) Keratin type II 
cytoskeletal 1 
 5.5/20  113.47  
(8) Keratin type I 
cytoskeleton 10 
 5.5/15  146.62  
(9) Keratin, type I 
cytoskeleton 10 
 6/16  195.72  
10 Ig Kappa chain C region P01834 5.8/30 5.58/11.60 130.36 6/79.2 
a
 Spot numbers from figure 7 a) and b) 
b
 Accession numbers acquired from Swissprot/Uniprot  
c
 Estimated pI/MW from 2D gel 
d
 Theoretical pI/MW computed from Expasy database  
e
 Significant scores were scores > 65 in Mascot. 
 () Spots classed as contamination, no positive identification were observed besides Keratin 
 
 
1
1
1
 
 
 
 
 
 
    
 
 Table 3.4: List of positively identified proteins, from the healthy and autistic samples 
Spot 
Numb
er 
a
 
Protein Name 
b
   Accession 
number 
c 
 
Protein spot presence 
in group
d
 
PDQuest analysis/significance 
e
 
Healthy Autistic Student’s t-test  Quantitatively 
Significant 
1 Uromodulin P07911 ++++++ ---------- Yes No 
2 Vitelline membrane 
outer layer protein 
homologue 
Q7Z5L0 ++++++ ++++++ Yes No 
3 Kininogen-1 P01042 ++++++ ++++++ No Yes 
4 Alpha-1-antitrypsin P01009 +++++ ++++++ No Yes 
5 Ig Kappa chain region 
C 
P01834 ++++++ ++++++ No Yes 
6 CD59 glycoprotein P13987 +++++ ++++++ Yes Yes 
10 Ig Kappa chain C 
region 
P01834 ++++++ ++++ Yes Yes 
a
 Spot numbers from figure 7 a) and b) 
b
 Protein name assigned from Swissprot/Uniprot 
c
 Accession numbers acquired from Swissprot/Uniprot  
d
 The presence of the protein spots found and excised from the experimental groups. The + indicates the level of protein observed 
in the group (++++++, present in all; ++++, present in only four; +, present in only one; -, none observed) 
e   
Spot selection based on two tests/analysis parameters. The Student T-test with a 90 % significance and an quantitative 
parameter of significance. (Quantitative limits were selected in an outer limit method, with 1.50 fold upper and 0.5 fold lower 
limits)
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3.5 Discussion 
Research in proteomic studies has been of great importance due to its potential in biomarker 
discovery for diagnostics and drug development. In this project, proteins were extracted from 
urine of healthy and autistic African-South African individuals. This was done to establish a 
urine proteome profile with success and furthermore to assess the usefulness of these 
proteomes resolved in 2D SDS-PAGE gels. Successful biomarkers have been identified with 
other diseases, an example would be breast cancer and the expression of the estrogen receptor 
(ER) (Weigel and Dowsett, 2010).  This has not yet been developed in autism even though 
few studies have been undertaken but up to date no reliable biomarker candidate exists 
(Momeni et al., 2012). Urine proteomics have been shown to produce positive results with 
the benefits of the type of biological material. However one should realize that there are 
limitations. Firstly the presence of impurities in the urine which affect the isolation of the 
proteins and secondly, to reach optimum conditions is a lengthy process. 
 
Due to the nature of physical and chemical variability of urine samples important purification 
steps were required for the preparation of the proteins. As urine is excreted as waste and 
impurities from the body are present. The presence of the high abundance proteins such as 
albumin becomes a concern because the smaller proteins are masked therefore preventing the 
identification of potential biomarker candidate proteins. Furthermore urine protein degrades 
easily due to handling as well as proteinases present in the sample. These factors pose a risk 
and have to be addressed. 
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Urine is known to contain a very high salt content which interferes in protein separation 
(Ferreira, 2007). Other drawbacks are the high abundance of certain proteins such as 
Albumin and Immunoglobulins (Igs). These molecules mask other proteins that are present in 
low concentrations by altering the migration of all proteins during electrophoresis. For early 
detection of diabetic nephropathy and cardiovascular disease, micro-albuminuria is deemed a 
clinical important marker (Barratt and Topham, 2007). Another main component present is 
the Tamm Horsfall Protein or known by the alias Uromodulin (Carvalho et al., 2002). 
Uromodulin is formed and secreted in the thick ascendant limb of the loop of Henle, and was 
found in amounts ranging from 20 to 200 mg (per 24 hours) (Carvalho et al., 2002). 
 
The conditions under which urine is investigated also plays a big role on the final product. 
Differences observed between proteomes are dependent on the following factors: health 
status, stress, sex, diet and physiological status and conditions. Other differences are also 
observed within an individual; depending on the timing of collections and the influences on 
the system during collections (Khan and Packer, 2006). Table 3.5 displays the end result from 
different collection sets with its benefits as well as the drawbacks.  
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Table 3.5: Urine collections and differences observed time dependent, (Modified from Dihazi 
and Műller, 2007)  
Urine collection 
method 
Advantage Disadvantage 
First morning void Free of : Dietary influences 
              Changes due to     
               physical events 
Hypertonic and concentrated 
Bacterial contamination 
Protein degradation 
Difficulty reproducing protein pattern 
Second morning void Less protein degradation 
Better patient control 
High reproducibility of results 
Free of : dietary influences, 
changes due to physical events 
Stable proteome 
Does not represent the process taking 
place over a 24 hour period 
24 hour void 
collection 
Monitoring of kidney function 
over a long period 
Lack of patient control 
High protein degradation 
Lack of reproducibility 
Contamination(overgrowth of 
contaminating  microorganism) 
Useful only when all urine is collected 
for the 24 hour period 
Standardisation for proteomics almost 
impossible 
Random spot 
collection 
Flexibility of collection( at any 
time of day) 
Less protein degradation 
Better patient control 
Easy to handle for proteomics 
Does not represent the processes taking 
place over a 24hour period 
Proteome is depending on dietary and 
physical activity 
Catheterizations of 
the bladder 
 Invasive 
Risk of introducing infection 
Risk of traumatizing the urethra and 
bladder 
Urine proteome contamination with 
blood cell proteins 
 
 
In the present study, urine protein profiles were mapped and resolved on 1D and 2D SDS-
PAGE gels. Protein spots were then mapped and proteins of interest identified using 
Electrospray Ionization (ESI) Mass spectrometry and the output data matched to the 
Swissprot database. The profiles were also representatives of albumin depleted urine samples 
against the opposite being albumin containing samples.  The removals of major proteins 
ideally aim at identifying proteins of smaller size and quantity that goes undetected. Here 
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albumin was removed, and from figure 3.1 scrutinizing the healthy and autistic samples, it 
was observed that the healthy samples appear affected by the step. In figure 3.2 the autistic 
1D profiles do not seem to appear affected by the step. Any differences observed could be 
noticed by the increase in bands throughout the samples in the un-depleted lanes as well as 
the depletion or decrease of band intensities in the un-depleted samples, figure 3.2. Also 
observed and reported here is that the method of acetone extractions does produce 
positive/useful results for urine extractions even with the suffering of salt interference which 
was eliminated with further steps of clarification by dialysis and lyophilizing.  
 
This study was done to evaluate the potential of 2D SDS PAGE followed by mass 
spectrometry analysis of the urine proteome and the use thereof in understanding ASD. As 
indicated the method can improve providing optimum conditions when albumin depletion 
step is incorporated, thus increasing the chance of the identification of lower molecular 
weight proteins.  
 
Though this was done and some differences were observed, more steps could be incorporated 
such as Immunoglobulin removal, uromodulin exclusion, and more importantly with regards 
to the groups (both healthy and autistic) itself, larger sample size and precaution to technical 
errors and contaminations. Though the Uromodulin displayed unexpected results, removing it 
can be just as vital, since it does fall under the concept of ‘larger more abundant proteins” 
masking smaller proteins. 
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Using PDQuest™, 10 spots were selected based on the significance observed in this program 
and peptide sequences were analyzed by ESI-MS. The work shows relatively good proteome 
profiles when compared to previous studies, marker proteins have been observed one such 
can be considered the Uromodulin protein for reasons to be discussed. The protein output can 
also been used as indicator of the condition of the kidneys, and indirectly could be used to 
estimate the value of the results although not done in this study.  
 
The results shown as in table above reports 7 identities of best matched observed between the 
experimental sequences and those in the database used. These spots were either observed in 
one group and not the other or observed to have been enhanced in either the control over the 
autistic and vice versa. The cut off for a significant ion score and for mass spectrometry 
identification in this analysis set was 65, with a threshold of 5% (p<0.05). 
 
3.5.1 Uromodulin/Tamm-Horsfall protein (THP) (UROM_Human: P07911) 
A protein discovered nearly 50 years ago, and considered as the most abundant protein is a 
gene product with an aptitude to work together with the immune system. Furthermore it has 
roles in renal inflammatory responses and urate metabolism (Turner, 2003, Sedor, 2010, 
Schmid et al., 2010). Uromodulin is also known as the Tamm-Horsfall protein. These 
proteins are heavily glycosylated proteins, and under reducing conditions present themselves 
at ~90kDa (Van Rooijen et al., 1999). Healthy individuals’ usually produce about 50 mg of 
Uromodulin per day and are regarded as safe and protected against ascending urinary tract 
infections, reducing the risk of kidney stone formations (Schmid et al., 2010).  
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In this study, this protein could have served as an indicator for healthy profiles by 
determining the output per day and could in turn add weight to the strength of how well the 
study was conducted or executed. Individuals suffering a defect or mutation in the gene are 
diagnosed with familial juvenile hyperuricemic nephropathy (FJHN) an autosomal dominant 
disorder and also a form of medullary cystic kidney disease (MCKD2) (Sedor, 2010). 
 
Here it was observed that the expression of this molecule was only present in the healthy 
individuals but not in the autistic (mass spectrometry confidence score of 262.69). This result 
does however not necessarily mean a direct link to autism since the function of this protein 
primarily focuses on kidney regulations. The fact that it was not observed in the autistic 
group in this work does need to be further verified and confirmed. If this is indeed the case it 
appeals as to whether or not these individuals may have kidney diseases or lesser forms of 
infections. Though kidney failures have been associated with autism, it has only been 
associated through mitochondrial disease. Autism mitochondrial disease (AMD) is a form of 
ASD where children suffering of AMD have a malfunction in the generation of cellular 
energy (Davi, 2010). 
 
3.5.2 Vitelline membrane outer layer protein 1 homologue (VMO1_Human: 
Q7Z5L0) 
This protein has two variants according to the Uniprot database, few studies have been 
conducted on the human VMO1 gene, however it share close homology with the chicken 
homologue. A study reported close homology for this protein between human, cow, sheep 
and camel (Shamsi et al., 2011). Gene ontology shows this protein to have roles in the 
formation of the chorion-eggshell and is required to maintain the shape of the egg in 
Drosophila melanogaster (The Gene ontology, 2012). Furthermore even though this protein 
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was observed in all of the samples, the healthy group displayed an enhanced expression 
pattern when compared to the autistic group. Very little was revealed from this identification 
and may render this molecule as a candidate for further investigation subject to significance 
and function.  
 
3.5.3 Kininogen-1 (KNG1_Human: P01042) 
Kininogen-1 has been reported to be differentially expressed in Down Syndrome (DS) 
individuals (Heywood et al., 2011). It was shown that this protein was up-regulated in DS 
pregnancies when compared to control pregnancies utilizing narrow pH range 2DIGE 
electrophoresis and MALDI-TOF and Tandem MS/MS (Heywood et al., 2011).  Autism have 
been identified or diagnosed independently from DS however, some individuals suffering of 
DS may be autistic as well, and therefore the two conditions  have been reported to exist in an 
individual (Vatter, 1998).  
 
The KNG1 gene has been studied, and there are two types of products known, high molecular 
weight (HMW) and low molecular weight (LMW) single chains glycoproteins (Kitamura et 
al., 1985). The results observed here displayed a confidence score of 170.67 with 10 unique 
peptides matched. Although the methods differ between this study and the DS study, 
similarly patterns were observed with regards the expression of this protein spot in the 
autistic group (more enhanced spot) compared to the healthy (refer table 3.1: Albumin 
depleted healthy and autistic selected spots). 
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The importance of this protein sheds light on the potential biomarker roles in DS. According 
to the Uniprot database, KNG1 are thiol protease-, thrombin and plasma-induced aggregation 
of thrombocytes inhibitors. Individuals absent of the HMW protein have been shown to have 
abnormalities of the Hageman factor-dependant pathway of coagulation, kinin formation, 
fibrinolysis and bradykinin discharge (Liu et al., 1977, Wu et al., 2010b).  
 
3.5.4 Alpha-1antitrypsin (A1AT_Human: P01009) 
Alpha-1-antitrypsin is considered the most “abundant circulating serine protease inhibitor 
present in serum with concentrations of 85–250 mg/dL”, (Russo et al., 2009). This protein 
has major roles in liver and gastrointestinal (GI) regulations and a mutation in this gene is 
associated with diseases of the liver, lung and GI (Russo et al., 2009). A1AT deficiency is a 
genetic condition and is classed as an autosomal recessive disorder (Kok et al., 2007). The 
primary function for this protein is the role of “inhibiting the destruction of neutrophil 
elastase, and the protection against pulmonary damage” (Kok et al., 2007). What marks this 
particular spot as interesting is the fact that the study conduct by Russo et al.,(2009) showed 
that autistic children had lower levels of this protein in serum when compared to normal 
children, and that those individuals were suffering from GI diseases, respiratory problems as 
well as hyperbilirubinemia as well as cancer. In the present study, although different sample 
type, the A1AT protein spots were observed to be more enhanced than observed in the healthy 
group (refer table 3.1: Albumin depleted healthy and autistic selected spots). Though autistic 
individuals were studied, the current study suggests and association and contradicts the Russo 
study. The results obtained could be due to the group size, Russo et al.,(2009) study’s 
incorporated 71 members of 16 families of autism to 18 controls and concludes “suggestive 
association between autistic children with regressive disease and A1AT deficiency”. 
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3.5.5 Immunoglobulin (Ig) Kappa chain C region (IGKC_Human: P01834) 
This protein was identified for spots 5 and 10 above and in both instances was observed to be 
qualitatively significant as the controls displayed more enhanced levels of expression when 
compared to the autistic group. This pattern was observed in both un-depleted and depleted of 
albumin groups. What could be considered interesting is the fact that both spots were isolated 
from two different gels, and that the MS results showed a difference in the estimated pI/MW 
values for each spot (5 and 10). The spots 5 and 10 were collected from the same portion in 
the gel but from different gels, one after albumin depletion (5) and the other with albumin 
(10). The difference in MS results could thus suggest a modification or cleavage of protein 
occurred during the albumin depletion step. Immunoglobulins (Ig) are molecules comprised 
of two of both light and heavy chains, of which kappa is a type of light chain and furthermore 
have two domains or regions, the variant (V) and constant (C) domains (Sitnikova and Nei, 
1998). They function as antibodies in response to the host immune system (Nextprot beta, 
2012). The fact that Ig kappa chain C region is expressed more in the healthy than the autistic 
resonates the importance of the protein to the immune system and its fragility. 
 
3.5.6 CD59 glycoprotein (CD59_Human: P13987) 
CD59 is a membrane glycoprotein of 18-20-kDa that acts as a protector for human blood and 
vascular cells against cell disruption/death and is assisted through the human serum 
complement proteins C5b-9, (Ninomiya and Sims, 1992). This protein is an inhibitor of the 
membrane attack complex (MAC) of complement found on blood cells, endothelia and 
epithelial cells (Meri et al., 1996). A deficiency of this protein results in chronic hemolysis 
and peripheral demyelinating disease (Nevo et al., 2013). The results observed for this 
protein revealed a greater level of expression (enhanced spot intensities) in the autistic group 
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than seen in the healthy group. Though the score for this protein were 67.02, it had 25% 
coverage (equivalent to 4 unique peptide matches).  The presence of this protein observed 
more in the autistic than the healthy does however require more evaluation and investigation. 
 
Given the fact that this study aimed at identifying differential proteins, to be considered as a 
significant factor, is the population in which this study has been conducted. It’s known that 
the South African population exhibits an extreme genetic diversity when compared to the rest 
of the world especially that of African lineage and within the African population. Though 
these changes were observed in this group, stringent methods were incorporated to keep the 
results as reasonable as possible. Since the group was boys, plenty of differences could be 
observed. The healthy boys of that age are very active, and with the different backgrounds 
could display numerous differences, yet this study required that urine samples be collected at 
the time of second void. This allowed for minimal protein degradation, and reproducibility 
which counts in favor of these types of studies. From table 3.1, it has been demonstrated the 
benefits of the different collections, and it can be seen that all the different collection time 
points have both advantages and disadvantages. Depending on the objective of the study, it 
can be chosen accordingly. When looking at the 1D and 2D gel images, it can be observed, 
that this collection choice did in fact have an accepted amount of differences, using PDQuest, 
it could be analysed and a few of corresponding spots across the groups were found. 
 
 
 
 
 
 
 
 
 
 
  
 123  
 
3.6 Conclusion 
The aim of this study was to establish urine proteome profiles of African-SA healthy and 
autistic individuals and in doing so, execute a comparative analysis of those profiles. The 
comparison was achieved, and spots were selected based on the significance observed in the 
t-test and quantitative analysis sets used in PDQuest. Though the results seemed distinct 
enough, secondary analyses could/may have been employed on different software for more 
accurate readings and stringent results. The purpose of this study ultimately was to see 
differences that could be used downstream for diagnostics. In conclusion, the hypothesis that 
differences in proteome profiles of urine of autistic children would differ compared to healthy 
children was found. This method could thus render potential proteins with further 
investigation and could be used for diagnostics in the future. 
 
3.6.1 Limitations of the study 
With all the benefits of urine as a source for protein studies it has been limiting in terms of 
results. The extraction of proteins is a very sensitive step considering that the sample is 
subject to protein degradation, bacterial contamination and interference from the actual 
collections and storage, (Dihazi and Müller, 2007). The size of the study plays a role in the 
results obtained. Only 6 subjects were used in both the healthy and autistic. Given the size of 
the SA population, a group size of 6-12 is miniscule and therefore the results cannot be seen 
as representative for the entire SA population.  
With respect to the identified spots, it is hard to conclusively state that these results are 
significant. The selective ethnic group results may differ drastically from another ethnic 
group type and may yield a whole different set of results. The proteins identified here also 
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may have undergone modifications, truncations, degradations, and thus may be preliminary 
results since no specifications was done for the identification of proteins, and no selective 
staining were incorporated.  Typically a variety  of versions  can be observed between genes  
and their products as well the amounts produced and “good  correlation has been observed  in 
only one third of the observed entities only” (Burkard et al., 2011). Thus the results or 
observed abundance of these proteins cannot be seen as direct expression from the respective 
genes.  
 
These results also add weight to the fact that autism is a multifactorial disorder. Several spots 
were identified of which a few can be related to ASD symptoms and cases depicting the 
diversity of the disorder and the spectrum, or as mentioned the umbrella concept. The 
spectrum does also pose a hard road, since no two individuals suffer the same symptoms, 
making it hard to focus on a few proteins. It would be premature to assume that a few 
proteins can render insight into the disorder. 
 
3.6.2 Future studies 
The way forward in research for autism in SA requires a more in-depth study. The sample 
sizes used in this study was very small taking into consideration the increase of autistic cases 
reported within the SA population and the increase of the population itself. A bigger sample 
group would thus generate more useful results. Furthermore, as a starting project, a general 
screening of proteins could be investigated in attempt to establish a more general profile, not 
excluding differences observed between the groups. An important factor in this study is the 
different ethnic groups.  South Africa is composed of multiple ethnicities and genetic 
diversity within these ethnicities exists. Since most studies were done in other populations, 
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the default setting should be done befitting the South African population based on its genetic 
background. 
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I am a Masters student in the Biotechnology department at the University of the Western Cape. As part 
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in the study outlined above. 
  
2.  I understand that the genetic material for analysis is to be obtained from a sample of the cheek cells 
I’m about to donate. 
 
3. I understand that the sample has been assigned a unique identification number and that there will be 
no link between my child’s name and the unique identification number. 
 
4  Since the sample has been collected anonymously it cannot be withdrawn from the study.   
 
5 The sample will be stored indefinitely. 
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8. At no stage will the sample provided be used for anything other than the analysis of biomolecules 
involved in autism. 
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UNDERSTAND AND MY QUESTIONS ANSWERED BY: 
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Mass Spectrometry analysis 
Method used By DR. Z. Macdonald (Molecular and Cell Biology Laboratory, University of 
Cape Town). 
After in gel digestion extracted peptides were dried under vacuum.  Peptides were re-
solubilized in 5 % acetonitrile, 0.1% formic acid loading buffer.  5 μL was injected onto an 
LC/MS system consisting of an 1100 Series liquid chromatograph, HPLC-Chip Cube MS 
interface, and an Accurate Mas 6530 Q-Tof mass spectrometer (all AgilentTechnologies). 
The system was equipped with an HPLC-Chip (Agilent Technologies) that incorporated a 40 
nL enrichment column and a 43 mm x 75 μm analytical column packed with ZORBAX 
300SB-C18 5 μm particles. Peptides were loaded onto the enrichment column with 97% 
solvent A (water with 0.1% formic acid) and 3% B (90% acetonitrile with 0.1% formic acid) 
at 4 μL/min. They were then eluted with a gradient from 3% B to 45% B in 20 minutes, 
followed by a steep gradient to 80% B in 5 minutes at a flow rate of 0.3 μL/min. The total run 
time, including column reconditioning, was 35 minutes. 
For protein ID the SwissProt database was searched using the Agilent Spectrum Mill 
software. Search parameters included a static modification on cysteine residues, a 60% 
minimum matched peak intensity, ±20 ppm mass tolerance on precursor ions and ±0.05 Da 
mass tolerance on product ions and two missed tryptic cleavages. A minimum of two high 
confidence unique peptide sequence matches were required for confirmed protein 
identification. 
  
 
 
 
 
 
